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Researchers have identified higher incidence rates and mortality rates among African 
American men (AAM) diagnosed with prostate cancer than they have among urban 
African American men. This quantitative descriptive study was conducted to measure the 
association between advanced stage and grade of prostate cancer, demographic location, 
and prostate specific antigen (PSA) levels over a 5-year period in AAM and European 
American men (EAM) in rural versus urban communities. This study addressed 4 
research questions concerning cancer grade, cancer stage, age, geographic location, PSA 
level, and the impact that each of these variables had on prostate cancer diagnosis in 
AAM in the United States. Social cognitive theory was used as a conceptual framework, 
which was to focus on AAM, and their behavior with prostate cancer diagnosis, in rural 
versus urban communities. The sample was derived from data collected from the 
Surveillance, Epidemiology, and End Results Program (SEER) database. The population 
sample size was greater than 20,000. These data were categorically analyzed using a Chi-
square test and a t test. Overall, the results of the study showed that there was a statistical 
difference in rural versus urban populations between AAM and EAM diagnosed with 
prostate cancer over a 5-year period, and when comparing AAM with EAM in urban 
versus rural communities over a 5 year period, there was a significant difference in men 
diagnosed with prostate cancers as well as a significant change among men annually 
diagnosed with advanced stage prostate cancer. Information provided may have 
implications for positive social change affecting both rural and urban AAM in reducing 
fear and promoting prostate cancer awareness. This awareness may reduce advanced 
stage or grade diagnosis in AAM in both rural and urban communities.
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Chapter 1: Introduction to the Study  
Introduction 
The lifetime risk of developing prostate cancer and possibly dying from prostate 
cancer is substantially higher among African American men (AAM) than among 
European American men (EAM); Smith, Cokkinides, Brooks, Saslow, & Brawley, 2010). 
Recent attention has been directed toward the reasons that higher rates of prostate cancer 
exist among AAM. Prostate cancer has been known to be the leading cause of cancer 
incidence among males in the United States across all races, and AAM have twice the 
risk of any other ethnic group to be diagnosed with advanced-stage disease (Hoffman et 
al., 2001). Cancer in general has become a major public health dilemma in the United 
States and throughout the world (Smith et al., 2010).  
There have been many studies on prostate cancer treatments in regard to racial 
differences, prostate cancer care, age, and multiple risk factors (Hoffman et al., 2001). 
This study was designed to address the differences in rural versus urban communities 
with a focus on the diagnosis, stage, and grade of disease; prostate specific antigen (PSA) 
levels; and knowledge of prostate cancer within each population. To investigate all 
factors, I calculated the differences in advanced stage disease that were associated with 
ethnicity, adjusting for demographic region and socioeconomic status. In this study, I 
looked at data over a 5-year period to determine whether there was a difference in 
diagnoses between communities. The study used secondary data collected from the 
Surveillance, Epidemiology, and End Results (SEER) database, and parameters were set 
to obtain the necessary data. 
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AAM have the highest incidence and mortality rates for prostate cancer, with 
these rates exceeding those of EAM ; Mohler, 2007). Several studies have indicated that 
differences in prostate cancer rates between men of different geographical origins may 
not be unique to the United States (Mohler, 2007; Smailyte & Kurtinaitis, 2008).  
Urologists have indicated that a new patient is diagnosed with prostate cancer in 
the United States every 3 minutes, and another patient dies every 17 minutes (Jones, 
Underwood, & Rivers, 2007). This study may support positive social change, in that it 
may provide AAM with tools to change their behavior in relation to trust and fear in 
regard to medical treatment, as well as with knowledge of prostate cancer. The burden of 
this form of cancer for AAM seems to be related to a complex interplay of social, 
cultural, and biological factors that have resulted in screening rates being low and the 
stage and grade of the disease being higher at diagnosis for this population. These 
patterns could result in diminished access to timely treatments and compromised quality 
of care. Healthcare providers must have a working knowledge of all of the barriers to 
cancer care experienced by AAM in order to contribute to effective treatment 
recommendations. Many patients confronted with receiving a diagnosis of cancer state 
that they are not equipped with sufficient information to make a decision on their 
treatment. Such patients may request that a physician make the decision for them; 
however, individuals would like to be fully informed (Forrester-Anderson, 2005).  
This chapter focuses on the history of prostate cancer in AAM compared to their 
counterparts. A major focus is the problems the disease causes among men, and to what 
degree researchers try to distinguish between AAM and EAM in terms of experiences of 
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the disease. Social change is discussed in relation to the significance of this study 
designed to address the understanding for education and screening programs among 
AAM. The ultimate goal of the study is to improve the level of knowledge that exists 
among AAM concerning prostate cancer. 
Background 
Prostate cancer is the most commonly diagnosed cancer and the second leading 
cause of cancer deaths among men in the United States (American Cancer Society, 2009; 
Centers for Disease Control and Prevention, 2013).  More than 192,000 men were 
diagnosed with prostate cancer and about 27,300 died of the disease in 2009 (American 
Cancer Society, 2009; Centers for Disease Control and Prevention, 2013).  Men in the 
United States have a 16% lifetime chance of being diagnosed with prostate cancer and a 
3% chance of dying from the disease within 5 to 7 years of diagnosis once they reach age 
65 or older (Aetna, 2002). The SEER database indicated that in 2014, there would be an 
estimated 233,000 new cases of prostate cancer and those 29,480 deaths would occur 
(Centers for Disease Control and Prevention, 2013).  As of 2014, men in the United 
States had a 36.3% chance of being diagnosed with prostate cancer at age 66 or older 
(Centers for Disease Control and Prevention, 2013). Over the last 10 to 12 years, prostate 
cancer has been on the rise in the United States (American Cancer Society, 2009; Centers 
for Disease Control and Prevention, 2013). Early detection is essential to men receiving 
effective treatment for prostate cancer.  Patients who undergo regular PSA testing have a 
higher likelihood of undergoing prostate biopsy and being diagnosed with prostate cancer 
4 
 
compared with men who do not undergo PSA testing.  PSA testing is available to all men 
and is the critical component of early detection (Aetna, 2002).  
Racial/ethnic disparities in health care may be a contributing factor to mortality 
from prostate cancer among AAM (Demark-Wahnefried et al., 1995).  Demark-
Wahnefried et al. (1995) found that a majority of AAM older than age 50 who knew 
about PSA testing reported that they had never been screened or had the test done. These 
inequalities often encompass the entire spectrum of care, starting with screening and 
prevention activities and programs, leading to diagnosis and treatment, and ending with 
palliative and end-of-life care (Heyns, 2008). 
AAM in the United States are diagnosed more often than EAM with advanced, 
incurable prostate cancer, mainly due to their more limited access to health care, their 
socioeconomic status, and their decreased participation in early detection programs 
(Mohler & Marshall, 2011). AAM have also been reported to be less likely to seek care 
for symptoms of prostate cancer because they frequently do not know about screening 
programs. In turn, treatment for prostate cancer is limited because the stage of the disease 
at which they are diagnosed is often advanced (Mohler & Marshall, 2011).  Prostate 
cancer is also biologically more aggressive in AAM than in EAM, as reported in the 
literature (Mohler, 2012). When AAM patients are diagnosed with potentially curable 
prostate cancer, they are less likely to choose an effective treatment, and at some point in 
time, treatment may not be offered to them (Mohler, 2012). 
Several factors may explain why AAM develop prostate cancer at a higher rate 
than EAM.  One factor may be lack of knowledge of the disease.  Cultural barriers must 
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be surmounted within the African American community when it is related to the 
stereotype of ignorance as a component of their heritage.  AAM have been labeled as 
individuals that do not have the knowledge to comprehend the severity of their disease. It 
is especially important that AAM and their families achieve a greater understanding that 
early detection leads to a better outcome for this disease.  
If knowledge of cancer prevalence increases, influencing priorities for research 
and the distribution of resources, cancer screening may become more beneficial to all 
cancer patients in all communities, not just AAM dealing with prostate cancer.  It is 
conceivable that no test for prostate cancer will ever be 100% sensitive (Mohler, 2012).  
Therefore, it may be the case that both “false negative” and “false positive” results 
leading to unnecessary treatment will always be present.  Despite the false negatives and 
false positives, most medical experts agree that screening for prostate cancer saves lives 
(Heyns, 2008). However, there is not enough evidence for experts to decide whether the 
potential benefits outweigh the potential risks when screening precedes treatment 
(Schiavo, 2007).  
Social disparity has been identified as a factor that makes a significant difference 
in prostate cancer diagnosis (William & Jackson, 2005). Socioeconomic status accounts 
substantially for differences between AAM and EAM in prostate cancer diagnosis (Bach 
et al., 2002). Decision making (related to treatment of prostate cancer)is much less likely 
to occur when AAM have lower levels of education and less health insurance along with 
distrust in health care providers and fear of losing their manhood (Smith et al., 2010). 
Evidence in the literature points to the idea that AAM do not receive the information 
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necessary to understand prostate cancer, or that they may not understand this information 
in the way in which it is presented to them in order to make a wise decision regarding 
treatment (Smith et al., 2010). Men and their physicians must talk more about the effects 
of prostate cancer at an early stage, with all necessary documentation presented to the 
patient. 
Disparities in treatment and health inequality have been noted as at least partly 
responsible for the difference in the status between AAM and EAM communities.  For 
example, the rate of prostate cancer in AAM is 10% higher than among EAM(Parham, 
2005). Many of the disparities that have been noted in the results of prostate cancer 
treatment among AAM are related to lack of understanding of the disease and available 
treatments, differences in socioeconomic status, differences in access to health care, lack 
of trust in health services, and perceived threats to manhood (American Cancer Society, 
2009). 
AAM have a higher risk of developing prostate cancer at an earlier age than men 
in other ethnic groups; this partly accounts for the poor survival rate of this disease in 
AAM (Parham, 2005).  AAM, when faced with prostate cancer decisions, need to have 
more information in order to overcome the burden related to the roadmap for future life 
expectations understanding what lies ahead for them(Oliver, 2007). 
The particular cause of this disease is not known to the degree at which 
researchers could identify a cure. However, deprived health, lower socioeconomic status, 
lack of education and knowledge, and lack of relationships with healthcare providers are 
indicators that point to factors for increased mortality rates for AAM with prostate cancer 
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(Jones et al., 2007).  There is a gap in the existing literature on screening and awareness, 
and these factors can affect the diagnosis of prostate cancer in AAM in relationship to 
EAM in rural versus urban communities. There is a greater amount of literature on 
treatment and prevention. This study focused on the diagnosis of prostate cancer in AAM 
compared to EAM in rural versus urban communities.  
Problem Statement 
The primary goal of any cancer prevention program is to reduce the effects of risk 
factors for cancer (American Cancer Society, 2009).  This goal is accomplished through 
identification and assessment of risk factors for cancer and development of interventions 
for cancer prevention at all primary, secondary, and tertiary levels (American Cancer 
Society, 2009). The literature indicates that treatment along with early detection can 
reduce mortality rates for prostate cancer patients (Mettlin, Jones, Averette, Gusberg, & 
Murphy, 1993). Mettlin et al. (1993) stated that 94% of EAM, when their tumors have 
been diagnosed at a localized stage, have a 5-year survival rate, compared to AAM 
diagnosed with advanced stage disease. 
AAM develop prostate cancer twice as frequently as EAM, and though genetics 
may play a role, dietary differences between these groups of men are clearly involved as 
well (American Cancer Society, 2009).  The incidence rate of prostate cancer in AAM in 
2010 was 192.9 per 100,000 men and was the highest among all ethnic groups reported 
(Centers for Disease Control and Prevention, 2013; Mohler & Marshall, 2011). 
Additionally, AAM in lower socioeconomic groups receive less consistent primary care, 
which correlates to the overall lower level of health in AAM (Barber et al., 1998).  
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Making AAM aware of the disparities of prostate cancer incidence in their communities 
should occur through education and screening programs (Oliver, 2007). What is unclear 
from the literature is whether these education and screening programs are having an 
impact on AAM. This study provides information about how education and screening 
impact the advanced-stage diagnosis rate in AAM. For this study, I investigated potential 
shifts in the proportion of prostate cancer over a 5-year (2008-2013) period in AAM 
compared to EAM; attempted to understand the level of knowledge AAM have, in 
comparison to CM, when being diagnosed with prostate cancer; and determined the 
amount of screening each group received before diagnosis in order to ascertain whether 
this reduced the rate of advanced-stage diagnosis of the disease in AAM. Although there 
is current controversy about the use of digital rectal examination (DRE) and PSA testing 
combined, providers typically conduct both tests when screening patients for prostate 
cancer (Smith et al, 2010). 
Social change can be created if it is learned that prostate cancer awareness and 
education are generating the preferred impact that would lead to reducing the incidence 
of prostate cancer in AAM. Nevertheless, in discussing ethnic groups, it is important to 
acknowledge the sociocultural aspects that explain both constructs and the correlations 
that exist in AAM risk factors(Deshpande, Sanders, Thompson, Vaugh, & Kreuter, 
2009).  With this in mind, social change will take an important step in the lives of AAM, 
while changing the culture of AAM as it relates to health behaviors. 
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Purpose of Study 
The overachieving goal of this quantitative study was to compare shifts in prostate 
cancer diagnosis in AAM in recent years to shifts in prostate cancer diagnosis in EAM 
during the same time frame. This research also compared the survival rate of AAM 
diagnosed with prostate cancer compared to EAM diagnosed with prostate cancer in rural 
and urban communities. Understanding derived from this study may lead to social change 
if prostate cancer awareness and education are creating the desired impact of reducing the 
incidence of prostate cancer in AAM. Literature, compared the education levels of AAM 
and EAM and provided insight on the impact of early detection and screening programs 
in each community. The communities this study addressed are rural communities and 
urban communities within the United States. Rural communities were defined as counties 
greater than 20 miles from a metropolitan area. This definition was based on the 
guidelines used for the SEER database. In this study, for example, Atlanta was 
considered a metropolitan area, and surrounding counties 20 miles or more from the 
Atlanta metropolitan area were considered rural communities. 
Significant differences exist in clinical presentation, sociodemographic 
characteristics, and health-related quality of life between AAM and EAM with prostate 
cancer.  This health-related quality of life difference persists after prostate cancer 
treatment (Mohler, 2012).  Quality of life in this context refers to the overall wellbeing of 
individuals with prostate cancer as they return to the communities in which they reside, 
reestablish their lives, and cope with behavioral changes. Although, as reported in the 
literature, prostate cancer is biologically more aggressive in AAM,(Mohler, 2012), 
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physicians should be aware that concepts of race and ethnicity are social constructs 
without direct relationship to biology and genetics (Mohler, 2012).  Prostate cancer is a 
major contributor to morbidity and mortality in the male population, but public awareness 
of this type of cancer has been limited (Agho & Lewis, 2001).  The lower level of 
knowledge among AAM compared to EAM regarding prostate cancer etiology and 
clinical factors highlights the need for educational programs on prostate cancer to target 
minority communities (Oliver, 2007).  Because of the fear of prostate cancer as a threat to 
their manhood that exists among AAM and their families, there is also a need for 
discretion on the part of physicians in their discussions of prostate cancer with AAM—
for example, by providing minority favored access to screening and through consultation 
with the patient without family members present (Barber et al., 1998). Important 
differences exist in access to screening, perceptions of the disease and its treatment, and 
knowledge of risk factors between the different racial groups in the United States. These 
represent significant barriers to early detection among AAM (Oliver, 2007). 
Research Questions and Hypotheses 
Identifying whether differences occur in treatment and outcome between AAM 
and EAM may help to determine why the diagnosis of prostate cancer differs between 
these populations and if there are differences in survival rate between rural and urban 
communities. Assessing differences in the stage of prostate cancer at the time of 
diagnosis between AAM and EAM populations in rural versus urban communities may 
establish whether these differences are related to the prevalence of the disease.  
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RQ1: Is there a significant difference between the proportion of AAM and the 
proportion of EAM annually diagnosed with prostate cancer in rural areas in the 
United States between 2008 and 2013?  
Ho1: There is no significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in rural 
areas in the United States over a 5-year period (2008-2013). 
Ha1: There is a significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in rural 
areas in the United States over a 5-year period (2008-2013). 
RQ2: Is there a significant difference in the proportion of AAM and the 
proportion of EAM living in urban areas in the United States annually 
diagnosed with prostate cancer between 2008 and 2013?  
Ho2: There is no significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in 
urban areas in the United States in a 5-year period (2008-2013). 
Ha2: There is a significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in 
urban areas in the United States in a 5-year period (2008-2013). 
RQ3: Was there a significant change in the proportion of men annually diagnosed 
with advanced-stage prostate cancer in rural versus urban areas in the 
United States between 2008 and 2013? 
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Ho3: The proportion of men annually diagnosed with advanced-stage 
disease in a rural community versus an urban community did not change 
during the 5-year period (2008-2013). 
Ha3: The proportion of men annually diagnosed with advanced-stage 
disease in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013).  
RQ4: Did PSA levels of men annually diagnosed with advanced stage prostate 
cancer significantly changes in rural versus urban areas in the United 
States between 2008 and 2013? 
Ho4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community did not 
change during the 5-year period (2008-2013). 
Ha4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013). 
Conceptual Framework for the Study 
This study, which focused on AAM and their behavior in relation to prostate 
cancer diagnosis in rural versus urban communities, was based on social cognitive theory 
(SCT). SCT involves an assumption that individuals will make reasonable decisions 
concerning whether one should take preventive action (Myers, 2005). SCT also signify a 
difference in the  structure of various life domains, such as family, health, demographic 
location, employment, and health care providers. SCT is a cognitive theoretical model 
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that includes many variables that assist an individual in performing and achieving valued 
goals. Figure 2 (presented in Chapter 2) depicts the framework that was employed for this 
study (Bandura, 1999). 
SCT was developed by Bandura (1999) for the purpose of each individual to 
express a type of control system that will have some interaction between the person and 
their environment or surrounding demographic area (Myers, 2005). This model was 
beneficial to this study because it served to assess the need for AAM to select specific 
responses to threats that may be related to health concerns, especially that of prostate 
cancer. This model consists of cognitive encodings, values, and goals and suggests that 
individuals select behavioral options to maintain physical, emotional, and social states 
within their communities. AAM with prostate cancer and their families have to manage 
the stress of the diagnosis, along with trying to interpret large amounts of complex and 
conflicting information on treatment options and to understand the outcome of what has 
been placed in front of them. Some studies suggest that SCT encourage individuals to 
gain personal success by observing others who have succeeded while facing similar 
obstacles (Bandura, 2009). 
The purpose of this study using the SCT framework was to describe the 
information sources that AAM have access to when confronted with prostate cancer, the 
decisions they make on health-related problems concerning the diagnosis, and the 
benefits and risks associated with the outcome of this decision making. SCT helped in 
determining whether demographic location and cognitive factors were independently 
associated with AAM who were treated or diagnosed at a cancer institutes or treatment 
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centers.  This study used data on PSA levels, which were monitored during the treatment 
of patients to assess symptom progress and could help in patients’ decision making 
moving forward. 
This study used standard demographic information, including age, race, 
geographical location, education, stage of disease, and PSA test value. SCT was the most 
efficient framework to address all of the needs of this study. Informed decision making 
encompasses knowledge, and a relationship between the patient and health care provider. 
Even with the awareness of the potential benefit of early detection, there may be concern 
regarding unnecessary surgeries for prostate cancer in AAM that is not life threatening. 
AAM may withdraw from and avoid a situation that seems too threatening or 
overwhelming. This may be the reason that AAM make the decision to remove 
themselves from cancer screening programs. 
Change is something that does not come easily to individuals; for this reason, 
SCT addresses the issue of perceived barriers to change. Individuals’ self-evaluation of 
any obstacles in the way of adopting change has an effect on these barriers and on the 
promotion of new behaviors. Individuals need to believe in the benefits of a new behavior 
before they will be willing to adopt a change (Centers for Disease Control and 
Prevention, 2013; Mohler & Marshall, 2011). 
Nature of the Study 
In addressing the research questions presented in this study; a retrospective, 
quantitative methodology was used to assess trends in prostate cancer diagnosis among 
AAM and EAM living in urban and rural areas over a 5-year period.  The SEER database 
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stores data on several geographical locations throughout the United States, such as cities, 
counties, and states, and is based on data from state cancer registries.  Secondary data 
routinely collected from hospital medical records are housed by the Centers for Disease 
Control and Prevention in the larger SEER database. This database provides a consistent 
source of information on prostate cancer that can be used for research purposes.  As such, 
the SEER database was used for the purpose of analyzing differences between AAM and 
EAM populations in urban and rural communities during the 5-year period of interest.  
This study investigated the reason for differences between AAM and EAM in relation to 
prostate cancer by evaluating ethnicity, income, and advanced-stage disease, adjusting for 
demographic region, socioeconomic status, clinical factors, and pathological factors. 
Analysis of the data involved both descriptive and inferential statistics. In order to 
identify patients with advanced-stage disease, the data were supplemented by abstracting 
data from a sample of hospital records at the Roswell Park Cancer Institute (RPCI) 
urology department.  
Definitions 
Digital rectal exam (DRE): Palpation of the rectum by a physician using a glove 
and his or her index finger in order to search for an enlarged prostate (Mohler, 2007). 
Health belief model (HBM): A highly used framework introduced by a cohort of 
psychologists associated with public health services for the purpose of establishing 
individuals’ beliefs and attitudes to determine their health-related actions (Rosenstock et 
al., 1988). 
Prostate cancer: A malignant tumor growth that occurs in the prostate gland of 
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men (Underwood et al., 2005). 
Prostate-specific antigen (PSA): Affected , treasured tumor marker; also the most 
clinically useful means to monitor disease recurrence after the treatment of prostate 
cancer (Polascik, Oesterling, & Partin, 1999). 
Quality of life (QOL): a measurement used to integrate objective and subjective 
indicators for a wide range of life domains and individual values (Felce & Perry, 1995). 
Socioeconomic status (SES): Often based on an individual’s income, education 
level, occupation, and factors such as social status in a surrounding community where the 
individual resides (Forrester-Anderson, 2005). 
North Carolina-Louisiana Prostate Cancer Project (PCaP): A multidisciplinary 
study of social, individual, and tumor-level causes of racial differences in prostate cancer 
aggressiveness (Schroeder et al., 2006). 
Social cognitive theory (SCT): A framework developed by Bandura in 1999 for 
the purpose of giving an individual a means to mediate interactions between individuals 
and their environment (Myers, 2005). 
Assumptions 
This study required the assumption that all data collected from the SEER database 
would have all information necessary in order for the individuals who consented to 
participate in the study to meet the inclusion criteria. Further, it was assumed that 
enhancing knowledge and awareness of the need for prostate cancer education for AAM 
in rural and urban communities had the potential to aid in early detection of this disease. 
It was thus assumed that this study might help to reduce the number of men diagnosed 
17 
 
with prostate cancer as well as the mortality rate throughout the United States. 
Many factors are used to promote a healthy understanding regarding prostate 
cancer as it relates to diagnosis, knowledge, and understanding. Observing these factors 
could cause individuals to have recall bias when asked certain questions pertaining to 
their health. It was assumed that the information received from their health care providers 
was correct and that areas of concern were addressed in this study. 
AAM, when compared to EAM, may avoid participating in prostate cancer 
screenings, which may result in the progression of advanced-stage prostate cancer (Jones, 
Steeves, & Williams, 2010). Untrustworthy patient-provider relationships, education, and 
lack of financial resources contribute to most screening delays (Jones et al., 2007). The 5-
year prostate cancer survival rate for AAM is lower than that of EAM in the United 
States (Jones et al., 2007). 
In rural communities, a lack of urologists and radiation oncologists may account 
for the frequency of advanced-grade prostate cancer (Smailyte & Kurtinaitis, 2008). Most 
prostate cancer patients in rural areas travel to urban areas for care; thus, it is possible 
that high rates of ultimate prostate cancer treatment for AAM living in remote, small 
rural communities reflect their care in urban areas (Smailyte & Kurtinaitis, 2008). If it is 
assumed that there is a scarcity of local cancer specialists or cancer treatment centers in 
rural areas, one may assume that AAM who reside in those areas have more limited 
treatment sources than those in urban communities.  Travel distance and specialized 
healthcare facilities may impact the type of care AAM may receive in rural communities. 
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Scope and Delimitations 
The participants of this study included AAM who had been diagnosed with 
prostate cancer and were at least 40 years of age. This study focused on identifying 
factors associated with intentions to test for prostate cancer risk for AAM and EAM. This 
study used the SEER database to gather data. 
The data collected for this study was determined by county, city, and state; this 
information was used to differentiate between rural and urban communities. SEER data 
encompass all cancer registries throughout the United States (American Cancer Society, 
2009). The PCaP data were differentiated from SEER data based on a geographic 
information system (GIS) coding technique for identifying addresses. The data reflect a 
5-year period between 2009 and 2013. This is considered a retrospective study consisting 
of secondary data. 
Limitations 
The major limitation of this study related to ensuring that the data were up to date 
within the SEER database. The men whose data this study chose were patients in an 
established heath care system in urban and rural communities. In terms of data collection, 
information on personal background, including family history of prostate cancer and 
accuracy of the SEER data, were based on self-reporting. A third limitation was not 
having data to determine whether social support was present and what the educational 
level of the patient was in relation to prostate cancer before diagnosis. A fourth limitation 
involved the interpretation of the data and lack of understanding of whether prostate 
cancer was a primary or secondary disease. A fifth limitation was the possibility of a lack 
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of culturally appropriate communication of information between healthcare provider and 
patient in relation to factors such as distrust, fear, and disconnect, which could affect 
whether the patient participates in prostate screening. The sixth limitation was the limited 
amount of data on individual cancers in rural areas. The final limitation involved 
determining how much data for prostate cancer was in the registries for patients aged less 
than 50 years. 
Significance 
Prostate cancer is the most common cause of death for AAM (American Cancer 
Society, 2009; Centers for Disease Control and Prevention, 2013).  Prostate cancer is also 
the most commonly diagnosed visceral cancer (Hoffman et al., 2001). Many theories 
have been developed to account for these facts, but there is no concrete evidence to 
indicate why these patterns occur.  Major factors could include delayed diagnosis and 
limited access to treatment.  Many AAM may not have medical coverage or may not 
receive regular medical treatment for personal reasons; by the time symptoms become 
evident for such AAM, the disease has become more challenging to deal with.   
Prostate cancer screening and education may both be significant strategies for 
reducing mortality rates in AAM. Most of all, the relationship between sociocultural 
individuality and patterns of disease risk, health behaviors in AAM, and delayed 
diagnosis have not been studied fully or documented and have not been well understood 
by AAM (Consedine & Skamai, 2009). Recognizing and understanding the risk factors 
associated with the development of prostate cancer, along with the outcome of delayed 
initial screenings and diagnosis, were important goals of this study. My aim was to 
20 
 
measure the relationship between knowledge, demographic variables, patient-provider 
relationships, and AAM awareness of the benefits of early detection and their decision to 
participate in prostate cancer screenings.  
Prostate cancer is the leading cancer diagnosis among AAM in the United States 
(Johnson, Saha, Arbelaez, Beach, & Cooper, 2004). It has been stated that higher 
mortality is coupled with late detection of the disease (Geronimus, Bound, Waidmann, 
Hillemeier, & Burns, 1996). The causes for higher rates of prostate cancer among AAM 
are not clear. The goal of Healthy People 2010 (2013) is to reduce incidence and 
mortality rates in conjunction with prostate cancer for rural and urban populations 
throughout the United States. Accomplishing these goals will require much more research 
throughout many communities. A change in the stage of the disease at diagnosis is seen 
in all ethnic groups throughout the United States (Haas, Delongchamps, Brawley, Wang, 
& de la Roza, 2008). 
Social change may be possible if it is learned that prostate cancer awareness and 
education are generating the preferred impact, which will lead to reduction of the 
incidence of prostate cancer in AAM in both rural and urban communities, as well as in 
their family’s involvement as it pertains to history of their prostate cancer. 
Summary 
Currently, the exact causes of prostate cancer remain unclear; however, age, race, 
culture, heredity, and diet have all been identified in the literature as contributory risk 
factors for this disease. Screening individuals who are asymptomatic is crucial, 
particularly when testing is precise, specific, and most importantly, cost effective.  
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Numerous studies have indicated that the increased number of men diagnosed 
with prostate cancer may be attributed to lack of knowledge and understanding about the 
risk factors and screening procedures for prostate cancer, especially for those individuals 
who are classified as being in a high-risk category such as AAM and for those men with a 
genetic history of prostate cancer. AAM have significantly higher prostate cancer 
mortality rates than any other ethnic group (CDC, 2003). 
Studies indicate that the decision to participate in prostate cancer screening is less 
likely to be made when AAM have low levels of education and is not receiving all the 
necessary information to make a wise decision concerning their healthcare (Deshpande et 
al., 2009). The role that insurance plays in care for cancer diseases, along with income 
and health status, may contribute to the later disease stage of prostate cancer at diagnosis 
(Griffith et al., 2007). A majority of men trust that if prostate cancer were a potential 
problem, their healthcare providers would explain the seriousness of this disease to them. 
The evidence points to poor provider-patient communication, along with a lack of 
understanding and respect for AAM culture among providers. 
AAM continue to experience a greater burden of prostate cancer diagnosis 
compared to any other ethnic group in the United States (Odedina, Ogunbiyi, & Ukoli, 
2006). There are more questions than answers when it comes to explanations for the high 
rate of prostate cancer in AAM. Recent studies have provided further evidence of high 
prostate cancer risk among AAM compared to EAM(Odedina et al., 2006). As there have 
been reported differences in prostate cancer among AAM, it has been stated that prostate 
cancer in AAM can be attributed to multiple factors, which include underreporting, lack 
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of diagnosis, limited access to healthcare providers, and the quality of cancer data 
systems (Odedina et al., 2006).  
Where do researchers go from here? Can they explain why AAM have been 
unduly burdened by prostate cancer, with higher death rates, later stage disease at 
diagnosis, and unequal survival rates compared to EAM? Chapter 2 provides insight on 





Chapter 2: Literature Review 
Introduction 
Prostate cancer historically has been known as the most commonly diagnosed and 
second leading cause of death among AAM in the United States (Steenland et al., 2011). 
The lifetime risk of an AAM developing and dying from prostate cancer is elevated by a 
factor of two as compared to EAM (Myers et al., 1999). It has been reported that AAM 
are at a substantially higher risk of being diagnosed with advanced-stage disease 
(Hoffman et al., 2001). 
Recent data have indicated that prostate cancer survival, when adjusted based on 
the stage of the disease, may not represent a disadvantage for AAM compared to EAM 
(Newcomer, Stanford, Blumenstein, & Brawer, 1997). What is indicated here is that 
because of the aggressive nature of the disease, there may not be a racial difference based 
on the risk of the disease (Wender et al., 2013). Agho and Lewis (2001) pointed out that 
several factors may account for why AAM develop prostate cancer at a much higher rate 
than EAM. The barriers related to the abovementioned factors include stereotyping, 
cultural barriers, and knowledge (Shelton, Weinrich, & Reynolds, 1999). 
Variance in the outcomes of prostate cancer treatment has not been shown to be 
due to delays related to lack of access to care along with problems associated with 
prevention and diagnosis: however, it may reflect the inferior quality of medical services 
in some underprivileged areas (Barnato, Lucas, Staiger, Wennberg, & Chandra, 2005). 
Minorities and low-income persons receive lower quality care and face more barriers to 
healthcare access (Koh, Graham, & Glied, 2011). Factors adding to differences in 
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healthcare include poverty, lack of access to healthcare, inefficient insurance, language 
and literacy barriers, and poor expectancies of the outcome of cancer treatment, along 
with physicians and the healthcare system (Shelton et al., 1999). Even though causes that 
restrain access to care are multifactorial, racial and ethnic disparities in healthcare 
contribute significantly to this problem in the United States. Research shows that AAM 
are in inferior health relative to EAM, and they experience more substantial obstacles to 
receiving care (Hughes-Halbert et al., 2007). 
Literature Search Strategy 
Information on this topic came from a systematic literature review, in which I 
retrieved information from multiple databases such as PubMed, Cancer Lit, and Medline. 
Google Scholar and EBSCO, accessed through the Walden University library, were the 
major search engines used to collect articles pertaining to this topic. The Roswell Park 
Cancer Institute library was also a resource for information on the subject. Other search 
engines included SAGE, Cochrane WebMD, and High Wire. The search terms used for 
the purpose of this review were prostate cancer, rural and urban communities, AAM, 
CM, DRE, and PSA. The literature reviewed encompassed a period of more than 20 years. 
Conceptual Framework 
This study was based on using SCT to focus on AAM in rural and urban 
communities in relation to their behavior concerning prostate cancer. SCT was a 
beneficial framework because it is a model that addresses cognitive encodings, values, 
and goals and suggests that individuals will select behavioral options for succeeding in 
maintaining physical, emotional, and social states within their communities. SCT has 
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been confirmed to have applicability to preventive health behavior and flexibility in 
cancer treatments; thus, it is a useful theoretical framework for prostate cancer studies. 
According to the literature, SCT, which is a cognitive theoretical model, consists of a set 
of interrelated variables that, when accurately documented and multiplicatively 
correlated, will identify the reason that individuals will be motivated to participate in 
health behavior studies (Rosenstock et al., 1988). Figure 1 demonstrates the framework 
that was used for this study (Bandura, 1999). 














Figure 1. SCT diagram. From “Social Cognitive Theory of Personality,” by A. Bandura, 
1999, in A. Pervin & O. P. John (Eds.), Handbook of Personality: Theory and Research 
(2nd ed., pp. 154-196). New York, NY: Guilford Press. 
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Prostate cancer is the most commonly diagnosed cancer throughout the United 
States, especially among AAM (Oliver, 2007). According to Oliver (2007), AAM are 
diagnosed with prostate cancer up to 65% more frequently than EAM. This disparity 
raises important questions about how it arises and how it impacts treatment of prostate 
cancer in AAM. Some of this disparity is related to a higher risk of inherited genetic 
factors contributing to prostate cancer in AAM (Odedina et al., 2006).  An additional 
explanation for this disparity, however, may be that AAM do not avail them of prostate 
cancer screening as frequently as EAM.  Oliver (2007) stated that the underlying reasons 
why this is the case are the subject of continuing study. 
Disparities 
Health disparities and health inequality have been noted to be related to a 
difference in the status of one group of people as compared to another group (Oliver, 
2007). Studies have shown overwhelming evidence that AAM receive substandard 
healthcare compared to EM in many geographical locations (Steenland et al., 2011). One 
of the goals of health care professionals should be to eliminate this disparity, specifically 
when it is related to cancer. Pursuing this goal is expected to lead to better health for all 
underserved populations with respect to many diseases in addition to prostate cancer.  
The disparity in prostate cancer care in AAM compared to EAM is particularly a 
problem in rural communities. Smedley et al. (2000) stated that there is a great deal of 
diversity among rural African American communities as compared to the U.S. population 
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as a whole, and most members of these communities experience disparities in their health 
care status (Hughes-Halbert et al., 2007). It is not clear whether this disparity is related to 
less frequent access to doctors, difficulties finding adequate health care facilities in rural 
versus urban populations, or perhaps fewer visits to health care facilities for other reasons 
(Oliver, 2007). It has been stated in the literature that one in every six American men will 
develop prostate cancer during his lifetime (Oliver, 2007). This being said, studies have 
also shown that AAM have the highest risk of developing prostate cancer and are twice 
as likely to die from this disease compared to EAM as prostate cancer patients (Oliver, 
2007). In the United States, men are 33% more likely to develop prostate cancer than 
American women are to develop breast cancer (Smart, 1997). A contributing factor is that 
there is far less public awareness of the need for prostate cancer screening promoted 
through television and radio advertisements compared to breast cancer screening (Oliver, 
2007).  
Morbidity and Mortality 
 Recent studies have shown that despite prostate cancer having a high morbidity 
and mortality rate, AAM far less frequently participate in prostate cancer screening 
compared to EAM(Oliver, 2007). One may speculate on the reasons for this fact. 
However, it has been suggested that there have not been any qualitative studies 
performed that shed light on why this phenomenon takes place (Oliver, 2007). Some of 
the factors cited as contributing to prostate cancer in AAM are age, family history, diet, 
and lack of health care information and understanding (Oliver, 2007). These factors, 
when combined with the reduced frequency of screening and absence of education for 
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AAM, could lead to some of the disparities that have been identified in prostate cancer 
morbidity and mortality within the African American population (Oliver, 2007). If 
researchers had a better understanding of one’s personal experiences with prostate cancer 
and screening of AAM, they might be able to develop more effective programs and 
targeted interventions for at-risk populations of AAM, as well as men of other ethnicities. 
 The effectiveness of prostate cancer screening based on current guidelines and 
information remains unclear (Oliver, 2007). The exam initially employed to screen for 
prostate cancer was the digital rectal exam (DRE).  After many years of employing the 
DRE an additional exam was developed, which is known as the prostate specific antigen 
blood test (PSA).  Both are employed to detect early prostate cancer (Demark-
Wahnefried et al., 1998). This study has shown that prostate cancer screening should be 
performed for all men of ages 40 to 70 (Oliver, 2007). This study consisted of 179 CM 
and 115 AAM (Oliver, 2007).The earlier prostate cancer is detected, the greater the 
probability of survival and the more likelihood there is for a healthy outcome.  
 In men, the incidence of prostate cancer increases dramatically with age (Oliver, 
2007). However the incidence of prostate cancer in AAM well exceeds that of their 
Caucasian counterparts. When looking at age as a risk factor for prostate cancer in CM 
who have no family history of the disease, the increased risk begins at age 50, while in 
AAM it begins at age 40 (Oliver, 2007). Although delayed screening has been identified 
as a possible reason for the differences in prostate cancer diagnosis in AAM compared to 
EM, other factors that have also been identified as likely contributors to this disparity are 
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lack of knowledge, communication, social support, quality of care, and perceived threats 
to men’s sexuality (Oliver, 2007). 
 Focus groups of older AAM have identified and examined the psychological 
factors that influence the screening behaviors among this group (Hsing & Devesa, 2001). 
Oliver’s study consisted of 26 males and 19 females who participated in the focus group. 
The findings of this study suggested that most individuals view cancer screening 
positively. Furthermore, it identified increasing age as a primary motivating factor to 
obtain any type of cancer screening (Oliver, 2007). Men in this focus group tended to 
express their distrust of the medical system and looked at cancer as a death sentence 
(Oliver, 2007). AAM were less likely to pursue cancer screening on their own and relied 
strongly on encouragement from family members (Steenland et al., 2011). 
Rural Versus Urban Populations 
Studies also suggests there is a difference in cancer staging among rural compared 
to urban population; rural population are diagnosed at a more advanced stage (Griffith et 
al., 2007). AAM in rural areas are particularly at risk of late stage cancer diagnosis. It is 
also documented that rural dwellers have less access to and are less likely to utilize early 
cancer detection programs (Goovaerts & Xiao, 2011). Even though numerous studies 
have highlighted the need for prostate cancer screening among AAM, no studies have 
addressed the concerns and attitudes of rural AAM about prostate cancer and cancer 
screening programs (Oliver, 2007). It has been suggested that rural AAM know very little 
about the symptoms of prostate cancer or what is involved in prostate cancer screening 
(Odedina et al., 2009). This could lead to embarrassing situations for individuals who 
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have no concept of what symptoms are associated with prostate cancer or what is 
involved in prostate cancer screening.  Additional knowledge in this regard would be a 
powerful tool. However, this knowledge is not always utilized because AAM often 
dismiss this knowledge because they view it as a threat to their manhood (Oliver, 2007).  
Most AAM have a problem verbalizing the fear that having a DRE will make them feel 
as if they are being violated (Oliver, 2007).  It has also been reported that because of 
these attitudes, African-American physicians and healthcare providers are reluctant to 
discuss prostate health information in ways that their patients will understand (Oliver, 
2007).   
All of these considerations point to a critical need for more research into the 
social, economic, and cultural barriers that contribute to the disparity in prostate cancer 
morbidity and mortality of rural populations of AAM, in addition to factors such as a 
shortage of professionals, geography, and distance (Oliver, 2007). Information provided 
by this research should prove invaluable to AAM, who can be influential in providing 
guidance to scientists and healthcare providers. It should also facilitate the adoption of 
educational materials and activities that are better suited for AAM as it relates to prostate 
cancer and screening for early prostate cancer (Oliver, 2007). 
 The disparity between prostate cancer cares for African Americans compared to 
Caucasians exists in urban populations in the United States as well, and in populations 
outside the United States. In 2002, the International Agency for Research on Cancer 
estimated that based on the incidence and prevalence of mortality from 27 cancers 
throughout all countries, prostate cancer ranked first among five year prevalent cases of 
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all cancers in men (Odedina et al., 2006). In 2005, United States cancer mobility and 
mortality estimates reported by the American Cancer Society indicated that prostate 
cancer will continue to be the leading cause of new cancer cases and the second-leading 
cause of cancer death in men (Odedina et al., 2006). A disproportionate burden is 
experienced by AAM, because of the 232,090 cases of prostate cancer that was reported 
in the year 2005, AAM were 2.4 times more likely to die from prostate cancer compared 
to EAM(Odedina et al., 2006). AAM also have the highest incidence of prostate cancer 
compared to other racial ethnic backgrounds in the United States (Odedina et al., 2006). 
Studies show that the differences in the incidence of prostate cancer and the variations in 
incidence among ethnic groups are caused by multiple factors, including genetic 
susceptibility, external risk factors, health differences, and cancer limited programs 
(Odedina et al., 2006). A complete understanding of the reasons for the ethnic variations 
in prostate cancer incidence within the United States remains undefined (Smart, 1997). 
An additional question that has not yet been answered is does prostate cancer disparity 
exist among the original source population of African Americans? 
 Prostate cancer morbidity and mortality rates tend to vary worldwide among 
diverse groups (Odedina et al., 2006). It has been stated that generally more developed 
regions have higher morbidity and mortality compared to less developed regions 
(Odedina et al., 2006). If one examines the incidence of prostate cancer among AAM in 
the United States compared to men in the rest of the world, can we conclude that it is 
higher in AAM? In the absence of any type of viable cancer registration system that 
would allow comparison of population-based information on prostate cancer incidence 
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and outcome, we cannot conclude that prostate cancer burden among AAM is higher than 
that of any other group (Odedina et al., 2006). Although AAM have the highest incidence 
of prostate cancer in the United States, African Caribbean men have the highest rate of 
prostate cancer in the world (Odedina et al., 2006).  
 AAM have an earlier onset of prostate cancer along with a higher PSA level at 
diagnosis, and have been diagnosed more frequently with an advanced stage of the 
disease along with a higher mortality rate compared to EAM(Thompson et al., 2001). The 
African American ethnic background confers a greater risk of disease with advanced 
stages, which signifies a poorer prognosis for AAM. This could reflect the later stages of 
the diagnosis and consequently poorer prognostic features of the disease in AAM, or it 
could reflect a biological difference in the disease (Thompson et al., 2001). Several 
studies have provided evidence to support the above theory (Thompson et al., 2001). 
However, the sample size from Thompson’s study was small and variables such as 
treatment type and patient characteristics were difficult to control (Thompson et al., 
2001). 
  Thompson’s study compared the survival rate between AAM and other ethnic 
backgrounds. The results of the study said that there was no difference noted between 
treatment assignments and ethnicity (49.3% of the patient population was AAM and 
50.2% were EAM and they were randomly assigned to the study) (Thompson et al., 
2001). AAM exhibited poorer survival compared to EAM in the study, most likely 
because of the later stage of the disease at which they were diagnosed (Thompson et al., 
2001). The investigators stated that the poorer survival among AAM was a reflection of 
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poor prognostic factors.  To control for this factor they employed a proportional 
hazardous regression model to investigate the mortality relationship between the 
compared groups (Thompson et al., 2001). Thompson’s study also showed that AAM 
were more likely to have locally advanced or metastatic disease accompanied by bone 
pain and a poor performance status. They were also diagnosed at a younger age and with 
a higher Gleason score and higher PSA levels (Thompson et al., 2001). Compounding 
variables also showed that African-American patients had an higher hazard rate for death 
(1.23 with the 95% CI = 1.04 to 1.47; this increase risk was statistically significant to a P 
= .018) (Thompson et al., 2001). 
 Researchers have suggested that arrays of care and health behaviors may affect 
the outcome of prostate cancer in AAM (Thompson et al., 2001). For example, early 
diagnosis in AAM may increase mortality compared to CM because when they are 
diagnosed earlier, they are less prone to follow-up with treatment. (Thompson et al., 
2001). Marketing research has shown that advertising methods to educate men on the 
beneficial aspects of early diagnosis are effective in some communities, but less in 
communities of AAM. This problem could be mitigated by offering educational programs 
at work or at church or through peer testimonials (Thompson et al., 2001). 
  The outcome of treatment for AAM and EAM has been compared in multiple 
populations in attempts to correct for variables that may affect the outcomes, such as 
access to healthcare (Thompson et al., 2001). The problem is these results contradict the 
results of other studies, and have not been shown to be beneficial in multiple studies 
(Thompson et al., 2001). One explanation for the differences in outcome between African 
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Americans and Caucasians may be that it reflects a difference in how these two groups of 
men access their healthcare, as was suggested in a study of Medicare beneficiaries in 
New York State (Thompson et al., 2001). Thompson et al., reported these differences in 
the literature as well as in two reviews of United States experiences documented by the 
Surveillance Epidemiology and End Results (SEER) program (Thompson et al., 2001). 
 Summarizing Thompson's study, AAM are at a statistically significant greater risk 
of death following their hormonal therapy for advanced prostate cancer (Thompson et al., 
2001). The study concludes that these ethnic differences are important and warrant 
further investigation to identify the cause of the differences and to subsequently develop 
more effective therapies (Thompson et al., 2001). 
 Multiple explanations have been proposed to account for the disparities related to 
stage of disease and diagnosis of prostate cancer in AAM (Reynolds, 2008). As stated 
earlier demographic characteristics, social economic status, and comorbidity are 
examples that may limit cancer screening in African American population and may 
contribute to the delay in diagnosis (Reynolds, 2008). In a study conducted by Hoffman 
et al. (2001) a different explanation was being looked at, the explanation pointed to racial 
differences in tumor biology which was linked to attributable differences in diet, 
molecular factors and hormonal differences. This explanation attributed to the more 
aggressive tumor theory, stating that African Americans having differences in the above 
mentioned factors will be candidates for aggressive tumor growth in the prostate 
(Hoffman et al., 2001). 
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 Hoffman and others (2001) conducted the study known as the Prostate Cancer 
Outcomes Study (PCOS), which was used to collect data from populations consisting of a 
cohort of men with newly diagnosed prostate cancer, in an effort to assess the effects of 
treatment which involved radiation therapy, or prostatectomy on patients that had a health 
related quality of life outcome. The data came from the tumor registry system from the 
National Cancer Institute's SEER program, which provided cancer incidence and the 
survival data on patients in the United States (Hoffman et al., 2001). The patients were 
selected based on age, ethnicity, demographics, and race (Hoffman et al., 2001). The 
study sample size total was 5,672 citizens from a total of 11,137 qualified prostate cases 
(Hoffman et al., 2001). 
 The PCOS study showed that AAM had the highest proportion of advanced 
disease (12.3%) compared to EAM(6.3%) (Hoffman et al., 2001). Among the men that 
participated in the cohort study African Americans were younger and less educated, 
economically deprived, and were less likely to have had a PSA test (Hoffman et al., 
2001). The study also showed that African Americans had the most comorbidity and the 
highest PSA levels (16.8%) than any other ethnic group (Hoffman et al., 2001). From 
observing these factors the study pointed out that AAM were more likely to be present 
with clinically advanced stage prostate cancer as compared to EAM within the same 
parameters (Hoffman et al., 2001). 
 Racial and ethnic disparities in the stage of prostate cancer diagnosis is an 
important phenomenon clinically because the survival of men is dependent on the stage 
of the disease (Hoffman et al., 2001). Prostate cancer mortality rate has been shown to be 
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higher in AAM then in EAM; however, the racial disparity disappears after adjusting for 
the stage of the disease between the groups as stated by Hoffman et al. (2001). The SEER 
report has shown that AAM survival rate is poorer across all stages of diseases (Hoffman 
et al., 2001). The SEER data was not altered for socioeconomic or demographic factors 
(Hoffman et al., 2001). AAM, who subsequently represented in a lower socioeconomic 
level, have been noted as having less access to healthcare and preventive services 
compared to EAM; in retrospect this factor can delay diagnosis and lead to advanced 
disease (Hoffman et al., 2001). 
Stage of Disease 
 The failure to explain differences in the stage by looking at income, employment, 
educational levels, and insurance suggests that socioeconomic factors may not represent 
access to healthcare equities between AAM and EAM(Hoffman et al., 2001). Researchers 
may want to obtain data from a source that shows the above-mentioned factors as they 
relate with men with prostate cancer. Lack of association between cancer stages and these 
factors may better explain the advanced stage of prostate cancer disease in AAM 
(Hoffman et al., 2001). Since there are no prevention strategies for prostate cancer to 
reduce racial disparity in the stage and survival from the disease, this may lead to offering 
AAM an aggressive screening program (Hoffman et al., 2001). Ultimately, any efforts to 
decrease prostate cancer mortality and incidence in AAM will have to address all factors 
associated with racial disparity and clinical stage of the disease along with diagnosis 
(Hoffman et al., 2001). 
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 Numerous reports show that AAM are present with a higher grade and stage 
tumors, along with serum PSA levels being higher, are less likely to receive definitive or 
curative treatment than Caucasians. The prognosis for AAM is worse when compared to 
CM (Heyns, 2008). Studies have also documented that AAM are present with a more 
advanced disease and the treatment for this disease is palliative rather than curative 
(Heyns, 2008). It may be suggested that race is an ill-defined concept or a socio-political 
deception instead of a biological or genetic entity, causing the use of self-identification to 
establish the race of a study population (Heyns, 2008). 
 Incidence of prostate cancer may vary as much as 90 fold between different 
populations with the highest rate being present among AAM and the lowest rate exist and 
Chinese men (Heyns, 2008). Epidemiology studies reported, since the late 1930s the 
incidence and mortality rates have been consistently increasing in AAM compared to 
EAM(Heyns, 2008).  The rates that were reported vary from 126.4 to 275.3/100,00 per 
year in AAM while during the same time the rates in EAM were 74.5 to 172.9/100,000 
(Heyns, 2008). The mortality rates during the same time were 46 to 71.1/100,000 per year 
among AAM compared to 22 to 33.8/100,000 between EAM(Heyns, 2008).  With this 
magnitude it shows that the mortality rate can be reported as 10 to 120% higher among 
AAM compared to EAM(Heyns, 2008). With the increase in incidence rate Heyns (2008) 
suggests that there is a correlation which exists between increases in diagnosis which is in 
alignment with the increase in incidence. Hoffman et al. (2001) suggested that since there 
are no prevention strategies for prostate cancer, reducing the disparities in stage and 
survival may necessitate providing AAM with aggressive screening. As the rationale for 
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his statement, Hoffman (2001) mentioned that since recent data suggests that declining 
incidence rates of advanced stage prostate cancer, along with an increase in clinically 
localized prostate cancer in men overall, may imply it has a connection with PSA testing. 
 Studies have reported that prostate cancer increases with age, whereas the peak 
age depends on the life expectancy of the population (Heyns, 2008).  AAM life 
expectancy is considerably lower than EAM as reported by several studies (Heyns, 2008). 
Reports show that there are no reliable age-adjusted mortality rates available for many 
countries (Heyns, 2008) suggesting that data could be skewed when comparing 
populations for significant studies. The calculation for reliable incidence and mortality 
rates depend on accurate facts especially as it relates to diagnosis and reporting of all 
cases, along with complete population statistics (Heyns, 2008). Multiple studies have 
indicated that socioeconomic factors decrease the awareness and limited access for 
utilization of healthcare which will contribute to the poor outcome in AAM even after 
adjusting for differences in disease characteristics for pretreatment of the disease (Heyns, 
2008). While scientific evidence is lacking, the incidence of prostate cancer among AAM 
and the mortality rate is due to the higher stage at presentation or lower curative 
treatment rather than biological tumor aggressiveness (Heyns, 2008). 
 Zeliadt and others have suggested that since 1992, in the United States prostate 
cancer mortality has been on the decline by more than 20% (Zeliadt, Potosky, Etzioni, 
Ramsey, & Penson, 2004). At present it is unclear as to the reason for the decline, 
however it has been stated that several changes did occur in the diagnosis and 
management of prostate cancer disease (Zeliadt et al., 2004). A study was put together 
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with the use of primary and adjuvant androgen deprivation therapy (ADT) with the use of 
a population base treatment (Zeliadt et al., 2004). 
 The purpose of this study was to determine if aggressive therapy has increased in 
EM over time as compared to the decrease in AAM within the same time (Zeliadt et al., 
2004). The study did account for age, socioeconomic status, grade, and coal morbidity 
(Zeliadt et al., 2004). It was noted that AAM were 26% less likely to receive any kind of 
aggressive therapy (Zeliadt et al., 2004). Racial differences are increasing when it comes 
to aggressive and conservative therapies (Zeliadt et al., 2004). Understanding the impact 
of any treatment pattern can be very critical to the outcome on patient survival and cost of 
the treatment (Zeliadt et al., 2004).The data for this study was collected from the SEER 
Medicare database. This database contain Medicare treatment claims history on patients 
with nonmetastatic prostate cancer at age 65 or older (Zeliadt et al., 2004).  
Diagnosis 
 Brawley (1997) has placed an emphasis on how prostate cancer is a devastating 
sickness that affects the death of many AAM.  His research was designed to focus on the 
need for preventing prostate cancer deaths at the rapid pace in which it has been reported. 
Brawley’s study discussed the use of PSA testing for screening, and discussed the 
potential harms of the test (Brawley, Ankerst, & Thompson, 2009). He stated that 
because AAM have been taught for multiple years to fear all cancers and if one is to find 
the best way to cope with cancer, it would be to detect it early and aggressively treat the 
disease (Brawley et al., 2009).   
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 Brawley’s study suggested that over diagnosis put the emphasis on screening as a 
mechanism to save lives (Brawley et al., 2009). It was suggested that over diagnosis will 
increase a proportion of men surviving the disease for 5 and 10 years (Brawley, 2012b). 
From this article, it seems that over- diagnosis and screening are simultaneously used 
when it comes to prostate cancer prevention. Brawley stated that if screening will 
diagnose some men earlier, they may live longer after the cancer was diagnosed, however 
they do not live longer than other men who had the similar diagnosis but were not 
detected with a screening procedure (Brawley, 2012b). The literature suggests that over-
diagnosis was an issue well before screening was popular (Brawley, 2012b). The 
literature on screening shows that there is a difference among the number of men who are 
tested at an event compared to the screening done within the relationship between 
physician and his or her patient (Brawley, 2012b). 
 Prostate cancer screening has been done at multiple sites, for example churches, 
fraternities, television events, fairs, and community centers. They have been occupied by 
politicians, athletes, and celebrities, which help generate the attendance for men to be 
screened for prostate cancer. Brawley speaks on how the potential harms of screening is 
never mentioned at such events, however he states that the emphasis is to save lives by 
having such screening events advertised (Brawley, 2012b). The American Cancer Society 
at one time put an accent on prostate cancer screening being done annually on men of 
certain ages; it was also stated that this will address men to make an informed decision 
when it comes to prostate cancer (Wender et al., 2013). 
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 Underwood et al. (2005) reported that prostate carcinoma among AAM is the 
most prevalent noncutaneous malignancies in the United States. The projection of 
prostate cancer death related to this malignancy was stated to be around 28,900 men in 
the United States in which 30% would be newly diagnosed prostate cancer in AAM 
(Underwood et al., 2005).  The study acknowledged that in comparison to European Men 
(EM), AAM have been diagnosed with a higher grade and advanced stage of prostate 
carcinoma and AAM are less likely to receive any definitive therapy (Underwood et al., 
2005).  Schapira suggested that there was a significant difference when it came to 
utilizing special treatment modalities as related to EM compared to AAM (Schapira, 
McAuliffe, & Nattinger, 1995). The basis for determining the difference was data 
collected from the Surveillance, Epidemiology, and End Results (SEER) (Schapira et al., 
1995).  Other investigators have reported similar results as Schapira; however those 
studies produced strong evidence that it was related to racial differences.  
 Underwood et al. (2005) reported that an effort was promoted to increase prostate 
cancer education, screening and early detection for AAM in the1990s.  Even though this 
promotion was started, the study showed that there was a strong racial difference 
displayed in treatment for prostate carcinoma with little information published to 
substantiate if Hispanic men are included (Underwood et al., 2005). The objective of 
Underwood’s study was to describe the trends that existed between racial and ethnic 
backgrounds (Underwood et al., 2005). The study also exhibited different treatment 
modalities for localized/regional prostate cancer between EAM, and AAM. There was a 
difference in the type of treatment that was administered to each group (Underwood et 
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al., 2005). This led to the basis for the racial difference within the groups as reported by 
the researchers. Some examples of the different modalities were androgen-deprivation 
therapy, expectant management, radical prostatectomy, external beam radiation therapy 
brachytherapy, and combination therapy. Literature suggested that for AAM at the stage 
of the disease the only option was radical prostatectomy, which decreased after time 
(Underwood et al., 2005). It was also stated that androgen-deprivation therapy was not 
available for public use as presented in the national seer data set, which skewed the data 
collection for this study (Underwood et al., 2005). The author stated that of all the men 
that had radical prostatectomy and external beam radiation, AAM were 64% less likely to 
receive the treatment as their counterparts (Harlan et al., 2001). Harlan reported that 
multiple studies have found racial differences exist in the receipt of major therapeutic 
procedures after adjustments are made for economic status, socioeconomic status, and 
insurance, along with the severity of prostate cancer disease (Harlan et al., 2001).  
 Understanding that there is a lack of scientific data for the best treatment modality 
for localized prostate cancer, making a consensus decision can be difficult for AAM and 
their physicians (Underwood et al., 2005). Because of the patient variables such as 
socioeconomic status, treatment outcomes, and lack of trust in the healthcare system and 
the physician variables such as clinical bias, and lack of clinician agreement towards the 
information which is essential for decision making, there are hindrances for AAM when 
it comes to deciding on the best treatment for localized/regional prostate cancer treatment  
(Underwood et al., 2005).  With this being said, it is important for researchers to 
understand how these cofounders may have a bearing on the treatment which is received 
43 
 
by AAM for localized/regional prostate cancer (Harlan, Brawley, Pommerenke, Wali, & 
Kramer, 1995). 
Knowledge and Education 
 Racial and ethnic dissimilarities toward treatment outcome are not understood in 
totality and more studies are needed to find the common solution for all populations  
(Underwood et al., 2005). AAM having mistrust in the healthcare system is well 
documented which leads to AAM being less likely to trust their physicians than EAM 
(Corbie-Smith, Thomas, & St George, 2002). AAM have the belief that they were being 
used as guinea pigs and exposed to unnecessary risk without giving consent to their 
physicians (Underwood et al., 2005). There is not enough information on racial 
differences when it comes to mistrust, however speculation could be that AAM having 
mistrust can lead to refusal for more invasive procedures. 
 As previously stated by multiple authors, men diagnosed with prostate cancer in 
the United States have been documented every 3 minutes, also every 17 minutes a man 
dies from the disease (Mohler, 2007).The literature noted that the worldwide incidence of 
prostate cancer is increasing annually, and AAM have a higher incidence and a much 
larger mortality rate than EAM (Mohler, 2007). In fact it was stated that AAM have the 
highest mortality rate of prostate cancer in the world (Mohler, 2007). Data has shown that 
invasive prostate cancer is much higher in AAM than EAM at a rate of 1.9 times greater 
in the age bracket less than 65 years, however it is 1.6 times greater in AAM older than 
65 years (Mohler, 2007).  
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 Mohler suggested that what is presented above does not indicate a difference in 
racial development of prostate cancer (Mohler, 2007). However it was indicated that 
clinical prostate cancer progresses more rapidly in AAM than European men, also once 
prostate cancer appears clinically it becomes more lethal in AAM (Mohler, 2007). The 
study showed that reasons for the disproportionate rate of mortality as related to prostate 
cancer in AAM can be placed in 3 categories: 
1. Racial differences with AAM and the health care system 
2. Biological differences between races 
3. Biological differences in the prostate tissue between AAM and EM (Mohler, 
2007). 
If one is to carefully understand the contribution of these areas, he or she must examine, 
understand, promote public resources for research, and intervention to eliminate racial 
disparity in prostate cancer mortality (Jemal et al., 2008).  
 AAM present with incurable prostate cancer more frequently than EM, the SEER 
data base reported that 29% of AAM have metastatic prostate cancer compared to 
European men at 19% (Mohler, 2007). Consequently, racial differences and the regularity 
of metastatic prostate cancer may come from racial differences due to healthcare based 
on socioeconomic status and participation in early detection programs (Demark-
Wahnefried et al., 1995). The literature suggests that lack of early detection behavior 
among AAM can be a factor in the outcome disparity generated among AAM as they are 
more than likely not receptive towards prostate cancer screening (Myers et al., 1999). It 
was stated that the benefit of PSA in early detection can be a benefit to AAM at an earlier 
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age than 65 mainly because it could decrease the mortality rate (Gilligan, Wang, Levin, 
Kantoff, & Avorn, 2004). Some of the factors that point to why AAM are not receptive to 
early detection programs are unclear, however it was mentioned that realization of 
personal risk, financial limitations, and literacy level are the factors presented as the 
reason this phenomena takes place. Another factor that was presented was that AAM and 
their families lived in rural areas and the death rate was higher in the rural areas when 
prostate cancer was detected (Mohler, 2007). 
Race may have a role in patient and physician interaction when it comes to the 
healthcare system (Robinson, Ashley, & Haynes, 1996). Socioeconomic status was 
mentioned as one of the reasons AAM would not participate in clinical trials (Mueller, 
Ortega, Parker, Patil, & Askenazi, 1999). When looking back on research, it was 
determined that the data was flawed when the factor was emphasized as socioeconomic 
variables along with poverty (Nelson, 2002). Even if these factors are corrected AAM 
still remain in the minority to receive curative treatment for prostate cancer in 
comparison to EAM (Hughes-Halbert et al., 2007). The decision making for prostate 
cancer treatment may be obstructed due to racial differences between AAM and their 
physicians. African Americans having a strong belief in their community, church, 
religion, and the traditional source for healing may also have an impact on the 
relationship between patient and physician. (Johnson et al., 2004). Research has indicated 
that AAM have no problem participating in prostate cancer early detection for care when 
the information given to them is culturally sensitive, clear, and the relationship between 
them and their physician are respected (Germino et al., 1998). Some of the viable factors 
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that can play a part in AAM having a better relationship with their physician are trust, 
competence, and a positive motive for the treatment. African Americans may utilize 
culture with several factors such as family, religious community, and homemade 
remedies before they accept professional help, this has a barren on the communication 
between AAM and their physicians. 
Disparities concerns relating to race have a great impact and divergent pathway to 
healthcare matters (Williams & Jackson, 2005). In most residential communities there is 
an influx of African Americans; the inequities in the neighborhoods include 
environments, socioeconomic circumstances, and most importantly medical care which 
are the factors needed to maintain racial disparities in health (Johnson et al., 2004). The 
abundance amount of African Americans dying in the United States is significantly 
higher than 30 years ago; a study suggests that 100,000 African Americans die every year 
and would not die if the death rates were comparable (Odedina et al., 2009). Trying to 
understand the racial differences in health is a monumental task to overcome. As stated 
previously, some of the factors that have a major role in treatment are socioeconomic 
status, education, income, and health practices. with the focus on education, research 
suggests that AAM who have not completed high school have the highest death rate when 
compared to their counterparts with the same education level (Williams & Jackson, 
2005). The death rate of AAM with a limited amount of college learning is still 11 times 
that of their peers with the same education (Hughes-Halbert et al., 2007). 
 Other factors that point to social differences are stress, segregation, and poor 
residential environments all of which have an impact on income as well as health and are 
47 
 
stated in the literature as efforts needed to identify points of intervention in the healthcare 
arena (Fiscella, Franks, Gold, & Clancy, 2000). Racial segregation in residential areas are 
one of the initial causes for racial imbalances in the United States (Harlan et al., 1995). 
There is evidence that supports changing the health policy so that societal domains can be 
recognized as on one accord with all society and not have any influence on the healthcare 
for African Americans (Williams & Jackson, 2005). 
 Many researchers have expressed how physical, cultural, and social factors 
influence health risk and behaviors when it relates to prostate cancer and AAM. 
However, not many researchers have explored how the environmental contents affect 
AAM prostate cancer treatment or early detection methods (Griffith et al., 2007).  A 
study conducted by Griffith et al. (2007) used focus groups from rural southern 
communities consisting of AAM and their counterparts. This study talked about how 
sociopolitical context can shape a man’s screening and treatment behaviors when it 
comes to prostate cancer (Griffith et al., 2007). What the study pointed out was that these 
proximal and distal health related factors could affect a man’s prostate cancer knowledge, 
the perceived risk, and readiness to pursue care and trust in the health care system 
(Griffith et al., 2007).  
 Several quantitative studies have examined factors that are related to AAM 
decision making regarding treatment (Courtenay, 2000). What these studies have not 
done was to look into the health care systems or community level factors that will 
influence the decision making process for AAM as it relates to prostate cancer screening 
and treatment (Griffith et al., 2007). Some of the critical areas for research are in the 
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social, cultural, economic, and political arena which will shape one’s health system or 
community health outcomes, yet these factors are frequently ignored (Griffith et al., 
2007).  Griffith et al.’s research was trying to focus on the structural approach for 
examining the environmental factors that have influence on screening and treatment 
outcomes in a community. However, the researchers did not want to focus on the 
characteristics of individuals with certain behavior patterns. 
 Even though, the primary mechanisms are not well defined, age, race, ethnicity, 
and culture are some of the factors which are used to measure prostate cancer in AAM. It 
has been stated that prostate cancer occur more in men over age 50; AAM have been 
diagnosed with prostate cancer at an earlier age and at an advanced stage of the disease 
(Germino et al., 1998). AAM tend to be diagnosed with advanced stage disease and the 
rate of survival within five years is lower than European men, making their rates the 
lowest in the world (Griffith et al., 2007).  Many reasons exist for the unfavorable 
outcome for AAM and prostate cancer. Some examples are differences in biology, stage 
of disease, lack of health care access, cultural factors, masculinity, trust in the health care 
providers and many more (Courtenay, 2000). While many physicians state that having 
routine examinations are a protective measure, there has been major disagreements in 
routine prostate cancer screening especially when it comes to PSA testing (Brawley, 
2012b).  The major question is what we really know about early detection mechanism 
related to prostate cancer. Many professional associations and organizations have stated 
that evidence is insufficient to suggest routine screening or even to not suggest routine 
screening (Griffith et al., 2007). 
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 Ultimately, the lack of consensus regarding prostate cancer screening creates 
ambivalence and consternation among health professionals and makes it difficult for 
conscientious men to make decisions about screening (Griffith et al., 2007). Griffith et al. 
(2007) reported that rural AAM have been the most under-studied group of all in the 
United States.  Effects from racial oppression along with poor resources in rural 
communities, can contribute in the disadvantage for AAM with prostate cancer (Griffith 
et al., 2007).  These disadvantages are linked to the disparities in the risk and health for 
AAM with prostate cancer in rural communities (Griffith et al., 2007). It has been 
documented that rural communities have poor health infrastructures, which lead to the 
population to have a difficult time accessing resources and opportunities to better their 
health care (Griffith et al., 2007). Griffith pointed out that people who reside in rural 
communities are more likely to be older and have poorer health care which makes them 
prone to be less healthier than people who live in urban areas (Griffith et al., 2007). 
 The health related incidents in past history has caused AAM to feel that they are 
misdiagnosed, receive unequal health treatments, and  subjected to unethical research, has 
led to skepticism, mistrust of the health service, and paranoia of having a health cultural 
differences (Griffith et al., 2007). A major factor related to the differential rates for 
unhealthy behavior in AAM is gender socialization which leads to the attitude about 
harming their masculinity (Courtenay, 2000). This gender socialization promotes the 
paranoia in AAM and causes them to be less likely to follow recommended guidelines or 
seek health care as well as information regarding prostate cancer (Griffith et al., 2007). If 
AAM live in rural areas, they may have poorer health status and no health insurance, as 
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well as higher rates of chronic illness, such as, heart disease, diabetes, and cancer 
(Griffith et al., 2007).  
 With all the factors being mentioned that are related to prostate cancer decision-
making, one of the less mentioned is the social environment. In the African American 
community racism is the social environmental feature. Racism will affect all resources 
and will directly and indirectly affect the health outcome of African Americans (Johnson 
et al., 2004). AAM are the most stigmatized or stereotyped individuals in the United 
States, along with being exposed to a wide range of social environmental factors which 
ultimately affect their health in an adverse manner (Griffith et al., 2007). Reviewing the 
health inequity is always compromised for AAM if it impairs an aspect of life from them 
such as a sexual relationship or jobs (Griffith et al., 2007). On the other hand a high 
priority is placed on being a provider, father, and spouse, which will lead to seeking 
better health care (Courtenay, 2000). Looking at the lifespan of AAM, some stress related 
items that will contribute to AAM having poor health behaviors and high mortality rates 
with prostate cancer are, gender socialization, economics, social marginalization (Griffith 
et al., 2007).  
 The lack of knowledge has been cited as a reason for AAM not seeking screening 
for early detection of prostate cancer (Bennett et al., 1998). Communication also plays an 
important role in AAM decision making for prostate cancer treatment, and it was stated 
that physicians do not communicate well when discussing prostate cancer concerns to 
AAM (Gilligan et al., 2004). Individuals trying to understand screening and treatment 
behaviors without looking into the larger picture for health care and social context will 
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show this not to be beneficial for AAM. Even though research is continuing on AAM 
with their experience with prostate cancer, there is important limitations in the research 
along with gaps in knowledge that researchers must address in the future (Griffith et al., 
2007). 
     Boehm described a study promoting education and screening programs to increase the 
knowledge and self-efficacy in AAM with prostate cancer (Boehm et al., 1995). This 
research was a qualitative study done in churches predominately occupied by African 
Americans (Boehm et al., 1995). The framework that the author used was social cognitive 
theory for the purpose to model the desired behavior between patients or clients (Boehm 
et al., 1995). The results of this study indicated that individuals must possess the 
knowledge and skills to be self-regulated for change in behavior (Boehm et al., 1995). 
Boehm wanted to evaluate how effective an educational and screening program would 
benefit AAM, and would they participate in one as long as their church provided it 
(Boehm et al., 1995). Health education programs traditionally have not been designed to 
support the specific needs of men that are associated with ethnic or racial minorities 
(Price, Desmond, Wallace, Smith, & Stewart, 1988). Although Price et al. (1988) study 
was a start it surely indicated that more research is needed on generating knowledge of 
prostate cancer for AAM as it relates to treatment and screening behavior changes. 
 Smith, Dehaven, Grundig, and Wilson (1997) developed a community based 
study that showed the factors affecting the knowledge of AAM and prostate cancer.  It 
was shown that AAM did not have adequate knowledge as EM when asked about 
prostate cancer screening and treatments (Smith et al., 1997). AAM are getting the 
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message about prostate screening. However, educational efforts need to be enhanced in 
order to reach the less affluent or as mentioned the less educated in order to change 
behavior (Hoffman et al., 2001). The study suggests that demographic, socioeconomic, 
and education are factors that affect the level of knowledge that AAM have when it is 
related to prostate cancer (Smith et al., 1997). Smith et al.’s study indicated that 19% of 
the sample scored high on the questions related to prostate cancer, and AAM did not have 
adequate knowledge (Smith et al., 1997). This study also indicated that physicians need 
to play an important role in educating AAM about prostate cancer during examination 
and subsequent follow-up examinations (Smith et al., 1997).  
Barriers 
 Socioeconomic status (SES) has been associated with cancer mortality regardless 
if the data is collected from individuals or different communities (Singh, Williams, 
Siahpush, & Mulhollen, 2012). Some of the data has shown to be different for different 
areas within the United States (Singh et al., 2012). Singh et al.’s research was set up to 
analyze socioeconomic status between rural and urban communities (Singh et al., 2012). 
This study examined racial patterns and health disparities between the least and most 
advantaged social groups, while looking at the population in rural versus urban 
communities (Singh et al., 2012). The research determined that there was a need for 
social and medical interventions (Singh et al., 2012). Although numerous studies have 
generated information between area based SES disparities, there is a major variation in 
United States cancer mortality rates corresponding to levels between rural and urban 
(Singh et al., 2012). However, not many studies have examined the impact of deprivation 
53 
 
and urbanization explaining if there is a difference in the mortality rates from prostate 
cancer (Singh et al., 2012).  
 Minorities and socioeconomically disadvantaged inhabitants’ medical care in the 
United States has been reduced (Underwood et al., 2004). Singh et al.’s study indicated 
that in 2009 18% of African Americans less than age 65 did not have health insurance, 
compared to 13% Caucasians (Singh et al., 2012).  Minorities with a low SES were less 
likely to delay needed medical care than Caucasians (Williams & Jackson, 2005). African 
Americans with SES disadvantages in the United States were more likely to live in 
neighborhoods that were undesirable, and environmental characteristics, ultimately 
putting them at risk of poor health care and health conditions (Singh et al., 2012). It was 
reported that in 2007 26% of African Americans lived in unsafe neighborhoods, and 27% 
were habituating in areas with litter and garbage on the streets (Singh et al., 2012). 
 Singh’s study had some limitations, because some of the documentation was not 
SES disparities in the mortality rates for cancer. They used county level variations, which 
opened the door for ecological fallacy, because the study analyzed their functions on two 
different populations that were based on ecologic variables (Singh et al., 2012). In 
addition, most SES studies are done on an individual level while this was done on a 
geographical area level; the data may be smaller than that of individual (Singh et al., 
2012). Singh wanted to display a relationship with social disparities and how it could 
contribute to the overall health inequalities that exist in the United States. 
Summary and Conclusions 
 Prostate cancer is a significant public health concern in the United States, and 
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with an improved prognosis if it is discovered at an early stage, it is crucial that the 
healthcare providers for AAM detect any abnormality to decide what treatment option 
may be necessary for future survival. The literature review for this study showed a wide 
variety of cofounders which may explain why prostate cancer is elevated among AAM. 
The information was based on data collected from men of all ethnicities in the United 
States. At present, the exact causes of prostate cancer are still a major research topic, 
never the less; age, race, life style, hereditary, and nutrition have all been identified in the 
literature as factors which have an influence on prostate cancer. My study may fill the 
gap that has been missing in the literature, and may extend the knowledge among AAM 
in the discipline. 
Various research studies indicate the prospective barriers for the increased 
number of AAM diagnosed with prostate cancer being contributed to the lack of 
knowledge and understanding about the risk factors. AAM have expressively higher 
mortality rates than any other ethnic group as stated by the Centers for Disease Control 
and Prevention (CDC) (Jemal et al., 2011). The conceptual framework for this research 
will focus on the use of the HBM, this model assisted in identifying the factors which 
may influence prostate cancer and individuals’ health related knowledge. This research 
will not only look at the knowledge and comprehension in regards to prostate cancer with 
in the AAM communities, the main focus will be a connection with rural versus urban 
communities, looking at those men who have a higher risk of being diagnosed with 
prostate cancer and comparing the data between the male populations in each community. 
In chapter 3, I will discuss the details of the setting, sample size, methods, and limitations 
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of the research. I will explain the measures that will be employed to protect the rights of 
human subjects used in this study. The procedures and study instruments necessary for 
data collection will be discussed, and the statistical data analysis used for analyzing this 




Chapter 3: Research Methods 
Introduction 
Prostate cancer has been specified as the most diagnosed cancer in AAM in the 
United States (Jemal et al., 2005). Geographic dissimilarities in prostate cancer mortality 
rates as well as incidence in AAM have been detected in the United States for a number 
of years (Jemal et al., 2005). Literature has not reported on the reason for the 
dissimilarities, especially in rural versus urban communities, as they relate to prostate 
cancer diagnosis among AAM and CM.  Most information reported in the literature 
regarding rural versus urban comparisons relates to treatment parameters for prostate 
cancer and not diagnosis.  
Perhaps more men are being diagnosed with prostate cancer worldwide; the trend 
may be for knowledge and prevention to come to the forefront. Unlike other cancers, 
prostate cancer typically progresses at a slower rate and has fewer symptoms in the early 
stage of the disease. Literature has reported that the incidence of prostate cancer is 
increasing in both high-risk and low-risk populations (Brawley, 2012a).  Figure 2 













Figure 2. Illustration of different steps in diagnosis. From “The North Carolina–
Louisiana Prostate Cancer Project (PCaP): Methods and Design of a Multidisciplinary 
Population-Based Cohort Study of Racial Differences in Prostate Cancer Outcomes,” by 
J. C. Schroeder et al., 2006, Prostate, 66(11), 1162–1176. doi:10.1002/pros.20449 
 
Prostate cancer diagnosis varies between countries and communities. Prostate 
cancer diagnosis in people under age 50 has been reported on a limited basis. Research 
indicates that 85% of men diagnosed with prostate cancer are 65 years of age or older 
(Harlan et al., 1995). Multiple factors may account for the wide differences in the 
reporting of prostate cancer to many cancer registries. Prostate cancer disease does not 
occur equally among men of different ethnic backgrounds or within the same community 
(Whittemore et al., 1995). Although there is a difference in mortality rates between AAM 
and EAM between the ages of 40 and 65 years, advantages and disadvantages within the 











This study used data collected from the SEER database, as well as from the North 
Carolina-Louisiana Prostate Cancer Project (PCaP). The purpose was to evaluate 
differences in rural versus urban communities and AAM versus EAM within these 
communities. The data that were collected from these registries were population-based 
data, which are routinely collected for research studies. The use of both databases was 
intended to answer the research questions that were derived for the basis of executing this 
project. This chapter focuses on the design of my research, the methodology, the 
population that the study encompassed, and the sample size determined for this research.  
Research Design and Rationale 
A quantitative retrospective non-experimental research design was used to collect 
data to substantiate the research questions and hypotheses. The design was a secondary 
analysis of data collected by cancer registries from SEER databases. Most of the data for 
this study came from a case-only study design that was conducted in specific counties 
and states based on SEER database criteria throughout the United States. This is an 
example of a population-based sample of AAM and EAM who visited these sites for 
prostate cancer treatment. 
The data in this study were secondary data concerning AAM and EAM, which 
were analyzed for the purpose of evaluating differences in the diagnosis of prostate 
cancer between the populations. Data for this study were obtained from the North 
Carolina-Louisiana Prostate Cancer Project for use in a multidisciplinary population-
based study design addressing differences in race and the aggressiveness of prostate 
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cancer through an evaluation of social and individual characteristics, as well as the level 
of the tumor upon diagnosis (Moore et al., 2012). 
The majority of the analyses done by PCaP evaluated the risk factors that are 
associated with the aggressive nature of prostate cancer in AAM (Schroeder et al., 2006). 
The analyses were classified according to the clinical grade, stage of disease, and PSA at 
diagnosis.  
The SEER data were analyzed from AAM and CM in different counties and states 
throughout the United States for purposes of evaluating a large sample of men diagnosed 
with prostate cancer. The data did demonstrate differences with regard to socioeconomic 
status, healthcare, and several other risk factors mentioned throughout this study between 
AAM and men of other ethnic backgrounds.  
This research design involved assessing the relationship that exists between AAM 
and EAM concerning prostate cancer diagnosis and knowledge. With this design, the 
intent of this study was to describe the characteristics of AAM compared to EAM in 
relation to behavior associated with prostate cancer diagnosis and to test the research 
hypothesis based on numerical data. This design was used to describe the different 
variables that exist between AAM and EAM in prostate cancer diagnosis and to explore 
the relationship between the variables, which were ethnicity, age, socioeconomic status, 
income, advanced stage of disease, and insurance. 
Methodology 
AAM, by all standards, experience excess mortality associated with prostate 
cancer when they are compared to EAM(Brawley, 2012a). Ironically, healthcare patterns 
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have shown that AAM are less likely to undergo prostate cancer screening tests than their 
counterparts in other ethnic groups. One theory as to why AAM will not use prostate 
cancer screening tests is related to their socioeconomic status, knowledge, and beliefs and 
attitudes concerning prostate cancer prevention. 
This study was designed to examine data from the SEER database to determine 
whether there is a relationship between the demographic locations and health-related 
beliefs of AAM. A prostate cancer consortium consisting of investigators from North 
Carolina and Louisiana conducts PCaP. These investigators come from major institutions 
such as the University of North Carolina, Louisiana State University, Duke University, 
Roswell Park Cancer Institute, Boston University, and many more. The SEER program of 
the National Cancer Institute is designed to provide information on cancer statistics. The 
SEER program is a population-based registry that covers the U.S. population over several 
geographic regions and is the largest publicly available data set for all types of cancers 
(Mohler, 2012). This study used this information with the goal of reducing the burden of 
cancer among populations in the United States subdivided between rural and urban areas. 
The data collected from SEER were used to address the research questions as they 
pertained to AAM and EAM living in rural and urban communities. This study analyzed 
data over a period of 5 years to confirm why AAM, at the time of diagnosis of prostate 
cancer, had advanced-stage disease. The data were used to formulate charts and graphs to 






The target population used for this research study of prostate cancer disparities is 
AAM located in a metropolitan or urban area and rural area that have been diagnosed 
with prostate cancer. This population was selected based on the data that suggest AAM 
has the highest incidence of prostate cancer than any other ethnic male background. The 
sample collected from the SEER database for this research was composed of AAM and 
CM with the age greater than 40.   
Calculating secondary data makes this study statistically manageable because the 
data has been determined. After analyzing the data, the outcomes lead to the finding of 
which group of AAM between the rural and metropolitan areas, have the lower incidence 
rate. Several factors as to why AAM are diagnosed with prostate cancer have been 
explored; cultural barriers have to be addressed within the African American community 
to fight the stereotype of ignorance as a factor.  Better understanding that early detection 
leads to a better outcome for this disease should be addressed among AAM. 
Sampling and Sampling Procedures 
Data that was reported by the Centers for Disease and Prevention (2013) 
suggested that the age-based statistics concerning AAM and the diagnosis of prostate 
cancer by age suggest that 6 out of every 100 men will be diagnosed with prostate cancer  
by age 60 within the next 10 years.  At the age of 70, there will be 7 out of every 100 
diagnosed. Centers for Disease and Prevention (2013) also reported that 20.1% of AAM 
would die from prostate cancer by age 65. This data is suggesting that AAM should begin 
being screened for prostate cancer at the age of 45 for early detection.  
62 
 
The study analyzed AAM between the ages of 40 and 70 within both community 
groups. This study also analyzed the total population of individuals reported to the SEER 
database with prostate cancer between the ages of 40 and 70 years. The sample size was 
based on the total population listed in the SEER database (age 40-70 years) related to 
prostate cancer diagnosis in rural versus urban communities. The number was chosen 
based on data received from medical records from the health facilities in the locations 
along with data that has been reported to the Centers for Disease Control and Prevention 
(CDC). Data was also collected from SEER databases. However, looking at the bases for 
my study community population is what leads to determining the sample size for the 
study. Therefore, indicating a way to increase the sample size to maximize the data for a 
near perfect analysis. 
Procedures for Recruitment, Participation, and Data Collection 
Utilizing cancer registries as a resource for collecting data for public health 
related research is a valuable asset. Cancer registries play a vital role in all research that 
is cancer related. Population-based cancer registries are setup to provide information that 
is essential for priorities related to public health along with monitoring programs that are 
essential to cancer. 
Every state in the U.S. has policies that mandate cancer reporting and the 
authorities set regulations that will govern the cancer registries. The data that will be used 
in this study will come from the SEER databases, which collects cancer data for virtually 
all states in the United States. By utilizing, the databases collecting data for rural and 
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urban communities will give this study a controllable mechanism for gathering and 
comparing the data.   
The data collected was transferred from a coding sheet into a Statistical Package 
for the Social Sciences (SPSS) version 21.0 and Statistics Data Analysis version 13.1 for 
Mac data files. Examining the plausible ranges for responses to the different variables by 
frequency distributions, scatterplots, descriptive and outliner using SPSS will provide the 
data methods for checking and cleaning. The data, which was collected for my study, 
focused on the PSA levels in men with advanced stage prostate cancer in AAM and 
EAM. A second-data set also focused on the advanced stage of prostate cancer that was 
diagnosed in AAM and EAM in both rural and urban communities over a 5-year span. 
The third set of data focused on the marital status, education and screening knowledge of 
AAM compared to EAM in both communities over the same time span. 
Statistical Analysis 
Descriptive statistics was used to analyze and develop data collected for 
demographic and prostate cancer diagnosis associated with the characteristics and the 
primary study variables accompanying my study. There are several independent variables 
in this study which consist of income, marital status, education, environment, health 
belief, DRE level, relationship with healthcare provider, and knowledge of prostate 
cancer. The dependent variables in the study consist of age, gender, PSA level, 
demographic location, grade and stage of diagnosis. Income will be determined by their 
annual salary. Marital status will be if the men are married or single. Education is 
measured by highest degree attained from elementary school up to and including graduate 
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level. Age is measured by years and months. Demographic location is measured from the 
cities, states, and counties they reside in.  
RQ1: Is there a significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in rural areas in the United States 
between 2008 and 2013?  
Ho1: There is no significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in rural areas in the 
United States over a 5-year period (2008-2013). 
Ha1: There is a significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in rural areas in the 
United States over a 5-year period (2008-2013). 
Descriptive statistics was obtained on all variables. All data was collected using 
the SEER database registry. Age, location, grade of disease, stage, ethnicity, and cancer 
type was measured using a nominal scale coded via SPSS 21.0 statistical package and 
STATA 13.1. Chi square test was conducted to display the variables that are significant 
to prostate cancer diagnosis related in this study. The baseline was determined by 
calculating the means, standard deviation, and frequency of distribution.  The SEER 
database is set to collect stage at disease, age at disease, cancer type, gender, and race. 
The same parameters will be set for research questions 2 which are, 
RQ2: Is there a significant difference in the proportion of AAM and CM living in 
urban areas in the United States annually diagnosed with prostate cancer between 
2008 and 2013?  
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Ho2: There is no significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in urban areas in the 
United States in a 5-year period (2008-2013). 
Ha2: There is a significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in urban areas in the 
United States in a 5-year period (2008-2013). 
RQ3: Was there a significant change in the proportion of men annually diagnosed 
with advanced stage prostate cancer in rural versus urban areas in the United 
States between 2008 and 2013? 
Ho3: The proportion of men annually diagnosed with advanced stage 
disease in a rural community versus an urban community did not change 
during the 5-year period (2008-2013). 
Ha3: The proportion of men annually diagnosed with advanced stage 
disease in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013).  
Descriptive statistics was obtained on all variables. All data was collected using 
the SEER database registry. Age, location, grade of disease, stage, ethnicity, and cancer 
type was measured using a nominal scale coded via SPSS 21.0 statistical package and 
STATA 13.1. Chi square tests were conducted to display the variables that are significant 
to prostate cancer diagnosis related in this study. I used a p value of < 0.05 to show the 
significant of prostate cancer diagnosis. The baseline was determined by calculating the 
means, standard deviation, and frequency of distribution.  The SEER database is set to 
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collect stage at disease, age at disease, cancer type, gender, PSA and DRE levels and 
race. 
RQ4: Did PSA levels of men annually diagnosed with advanced stage 
prostate cancer significantly changes in rural versus urban areas in the United 
States between 2008 and 2013? 
Ho4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community did not 
change during the 5-year period (2008-2013). 
Ha4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013). 
The statistical analysis was performed using the SPSS 21.0 statistical package. 
The patients chosen characteristics was described using summary statistics. P-values for 
comparing AAM and EAM characteristics between prostate cancers was calculated using 
chi square test to display the variables that are significant to prostate cancer diagnosis 
related to this study. I utilized a p value of < 0.05 to show the significant of prostate 
cancer diagnosis. The baseline was determined by calculating the means, standard 
deviation, and frequency of distribution.  The SEER database is set to collect stage at 
disease, age at disease, cancer type, gender, PSA level, DRE level, and race. A two -
sample t-test was used to compare age for all data collected. A Kaplan-Meier 
proportional hazard model will be used to compare overall survival between each male 
group associated with my research. 
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Threats to Validity 
When diagnosis is a part of the decisions made by physicians and patients, 
different randomized trials have to be taken into account (Cooperberg et al., 2004). 
Relatively the amount of patients that are reported to the databases are under graded or 
under staged before surgery (Cooperberg et al., 2004). Relevance will depend on external 
validity in regards to the results being applied to a definable group of men in a certain 
clinical venue situated within a certain practice, example Urology. Most of the 
governmental agencies, pharmaceutical agencies, and medical journals tend to omit 
external validity which allows for the physicians to make judgments when diagnosing 
patients (Cooperberg et al., 2004). Some literature suggests that reporting of the 
determinants from external validity in systematic reviews are found to be inadequate 
(Skinner & Schwartz, 2009).  
Interpretation of evidence reported to the databases can also have an external 
validity of the studies the data was reported. The limitations that are within the evidence 
base studies will not always permit a clear interpretation of the different barriers 
associated with the cancer trials. A major variable for a physician in explaining the 
survival differences between AAM and EAM is the stage of the prostate cancer at 
diagnosis (Price, Colvin, & Smith, 1993). Studies have found that perceptions have a role 
in cancer risk reduction early detection behaviors along with diagnosis (Underwood, 
1992). 
Internal validity can be threatened by the bias collection of data from the cancer 
registries and how it was reported. Some studies suggested that the reliability of survey 
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data that may have been collected and used in studies may pose a threat to the internal 
validity (Price et al., 1993). Outcome data may be speculative because of selection bias 
making it difficult to interpret. Therefore making selection bias a threat to internal 
validity for this study as well as others. 
Ethical Procedures 
The collection of this data was subject to Institutional Review Board (IRB) 
approval. This approval has to be recognized because the data was collected from cancer 
registries. The desire is that the secondary data has been approved from the collecting 
sources leaving for little doubt that it is justified for research use. All rights will be 
protected using the appropriate measures such as signed documentation letting 
individuals know that the information may be used in future research studies. The 
purpose of this is an attempt to insure that The Health Insurance Portability and 
Accountability Act (HIPAA) were not violated. The data collected for this study was 
designed not to identify any candidate and is based on different cofounders, which are not 
identifiable for any group. 
No surveys or direct patient contact was used to obtain data. It was assumed that 
since the data was coming from secondary source the consents and other legal documents 
have been completed for the data to be published in the SEER database. Guidance on this 
provision will be sought from the IRB and the cancer registries used for this study. The 
IRB will provide an ethical framework from which the ethical review process for this 
study will operate. Although the most of the data archives which service the research 
community deal absolutely with the storage and provision of data collected for 
69 
 
quantitative research, the same facilities also will store, deposit and reuse data which was 
collected for qualitative research. Such data then can be used in the analysis for 
secondary data as used in my study. This data will be stored in a database created by me 
for a period of ten years. 
Summary 
 Numerous explanations have been intended to account for the disparities at the 
time of diagnosis. Some of the disparities mentioned are demographic characteristics; 
socioeconomic status and race are just a few that can limit screening in AAM and cause 
for the delay in diagnosis. Furthermore, attempting to explain the difference in disparities 
in the stage during diagnosis between AAM and EAM is difficult because there are no 
studies reported as of yet that assembled a large enough cohort to collect individual-level 
data to substantiate the information needed. 
 Efforts to limit prostate cancer in AAM as related to mortality will have to be 
addressing the disparity concerns at the clinical stage at diagnosis. Future studies will 
have to take place in order to explain such disparities as the socioeconomic factors, use of 
healthcare systems, distance to travel to healthcare facilities along with health beliefs. 
 Prostate cancer is the leading cancer diagnosed in AAM in the United States. 
AAM have been reported in the literature to have the highest incidence rate of prostate 
cancer in the world. AAM suffers from a higher disproportionately burden of the disease 
than any ethnic group in the United States. Removing race from the equation as an 
independent disparity, with all the other disparities mentioned, we would still have to 
answer the question what is the reason for worse pathological findings in AAM when it 
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comes to prostate cancer. The leading forces that emerge on how culture can influence 
attitudes, beliefs, and decision-making are attributed to lack of knowledge, 
communication, social support, quality care, and race. 
Prostate cancer in AAM has a realistic chance of early diagnosis in all areas of all 
states as long as education is delivered to all ethnicities. Many counties do not have the 
means to treat prostate cancer in rural areas and with the population being as high in 
North Carolina with African Americans travel, socioeconomics, and poor health care 
coverage play an important role in the outcome for proper treatment of the disease. AAM 
need to have an understanding of the outcome of prostate cancer if not diagnosed early or 
treated. 
This study was designed to examine data from PCaP database along with the 
SEER database to show if there is a relationship among the demographic locations and 
health -related beliefs of AAM. Chapter 4 will discuss the results gathered from the 
collection of data retrieved from the SEER database. This chapter will give a detailed 
outline showing how the data was put together to obtain the necessary results to 




Chapter 4: Results 
Introduction 
This chapter encompasses the findings from testing the hypotheses that were 
generated from the research questions of this study. A quantitative retrospective non -
experimental research design was used to collect data to substantiate the research 
questions and hypotheses. This design was a secondary analysis of data collected by 
cancer registries from SEER databases. The purpose was to show the differences between 
AAM and EAM in rural versus urban communities based on prostate cancer diagnosis. 
The methodology described in Chapter 3 was used to test the research questions and 
hypotheses listed. 
RQ1: Is there a significant difference between the proportion of AAM and the 
proportion of EAM annually diagnosed with prostate cancer in rural areas in the 
United States between 2008 and 2013?  
Ho1: There is no significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in rural 
areas in the United States over a 5-year period (2008-2013). 
Ha1: There is a significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in rural 
areas in the United States over a 5-year period (2008-2013). 
RQ2: Is there a significant difference in the proportion of AAM and the 
proportion of EAM living in urban areas in the United States annually diagnosed 
with prostate cancer between 2008 and 2013?  
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Ho2: There is no significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in 
urban areas in the United States in a 5-year period (2008-2013). 
Ha2: There is a significant difference between the proportion of AAM and 
the proportion of EAM annually diagnosed with prostate cancer in 
urban areas in the United States in a 5-year period (2008-2013). 
RQ3: Was there a significant change in the proportion of men annually diagnosed 
with advanced-stage prostate cancer in rural versus urban areas in the United 
States between 2008 and 2013? 
Ho3: The proportion of men annually diagnosed with advanced-stage 
disease in a rural community versus an urban community did not change 
during the 5-year period (2008-2013). 
Ha3: The proportion of men annually diagnosed with advanced-stage 
disease in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013).  
RQ4: Did PSA levels of men annually diagnosed with advanced-stage prostate 
cancer significantly change in rural versus urban areas in the United States 
between 2008 and 2013? 
Ho4: The PSA levels of men annually diagnosed with advanced-stage 
prostate cancer in a rural community versus an urban community did not 
change during the 5-year period (2008-2013). 
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Ha4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community changed 
significantly during the 5-year period (2008-2013). 
This chapter consists of four sections: introduction, data collection, results, and 
summary. A series of statistical analyses were performed to investigate and test the 
hypotheses that were generated from the research questions. Results are presented 
according to the statistical tests performed. STATA and SPSS statistical software were 
used to analyze all data collected. A summary provides the results revealed in this 
chapter. 
Data Collection 
Data were obtained from the SEER database cancer registry. In order to obtain 
data from SEER, one must register and abide by the rules and regulations for using the 
data. I obtained permission to use SEER data for this study in June 2014. The data use 
agreement for the 1973-2011 SEER Research Data File was signed and approved 
(Appendix A). In order to extrapolate the data, I used Statistics Data Analysis (version 
13.1), which is the software required by SEER to analyze data from the SEER database in 
order to separate and align the data based on the variables selected. 
This study used secondary data, which were reviewed and approved for the cancer 
registry associated with SEER. The variables chosen for data collection were age, race, 
marital status, risk, demographics, PSA, and Gleason score. Each variable was coded 
using the Rural Urban Continuum codes for use with SEER*Stat. 
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In explaining how the original data were determined, I wrote each code into the 
software, specifically assigning the task that I wanted the data collected for use in this 
study.  For example, using the continuum code for the county of Allen, Louisiana, is 
22003, but in the software it is represented by stating replaces metro if StCtyRec==22003 
to determine if it is rural or urban demographics. The purpose was to show how the 
software has to be coded in order to generate data. This was done after rural-urban 
continuum codes for 2003 and 2013 were defined in the software. After codes were 
written and labeled, I put them into a do file, which the software recognized, and I ran the 
file, collecting the data and putting the data into a Malgen folder designated for prostate 
cancer data.  The do files are a storage component of the software for placement of codes 
to be generated when run is selected. The codes were specifically designed to collect 
prostate cancer data and generate the analysis for the data collected. The datasets 
contained information on the variables of age, race, demographics, marital status, PSA, 
and Gleason score to determine stage of disease and risk of disease, along with diagnosis. 
After the data were generated, I had to analyze the data within the software to assure that 
this data was exactly what I was looking to accomplish. 
Upon all data being collected, I analyzed the data using STAT (version 13.1) and 
SPSS (version 21). The data were put into the statistical programs to generate tables and 
graphs to be used for this study. I analyzed using chi-square test, 95% confidential 
interval, and p value to show significance along with analysis of variance. I also ran the 





Table 1 through Table 5 show the total population in the United States as a whole, 
without separating the population between rural and urban communities. These data give 
the frequency and percentages of men diagnosed with prostate cancer and are determined 
by age and race in Table 1. The findings were analyzed using statistical analysis with chi-
square test and p value. The data showed that AAM have significantly higher diagnosis 
rates of prostate cancer than EAM(p < 0.0001). 
Table 1 
Frequency of Men Diagnosed With Prostate Cancer Based on Age and Race 
Race < 50 yr. 50-59 yr. 60-69 yr. 70-79 yr. > 80 yr. 
AAM 2851 (6%) 13387 (29%) 18659 (41%) 9343 (20%) 1624 (4%) 
EAM 6595 (3%) 51507 (21%) 98141 (41%) 66098 (28%) 16291 (7%) 
Total 9446 64894 116800 75441 17915 
Note. Chi-square = 3.8e+03. p value = < 0.0001. 
Table 2 describes the total population of U.S. men diagnosed with prostate cancer 
by marital status and race. This information shows that unmarried AAM have a higher 
percentage of diagnosis with prostate cancer in comparison to unmarried EAM (p < 
0.0001). For EAM who are married, the percentage is higher than that of AAM. This 





Frequency of Men Diagnosed With Prostate Cancer Based on Married or Not Married 
and by Race  
Race Not married Married Total 
AAM 19781 (43%) 26084 (57%) 45865 (100%) 
EAM 64670 (27%) 173971 (73%) 238941 (100%) 
Total 84451 200055 284506 
Note. Chi-square = 4.73e+03. p value = < 0.0001. 
 
Table 3 shows the PSA levels between AAM and CM based on total population 
throughout the United States. PSA levels are displayed in values of less than 1 up to and 
including greater than 20. AAM have a significant difference in PSA levels when 
compared to CM (p<0.0001). 
Table 3 
Frequency of Men Diagnosed With Prostate Cancer Based on PSA Levels 
Race PSA <1 PSA >1 PSA >2 PSA >4 PSA >10 PSA >20 
















Total 5453 7934 33912 181769 41549 13889 




Table 4 represents the stage of disease that AAM and EAM have in the United 
States. The percentages confirm that AAM are diagnosed with advance stage disease at a 
higher rate than EAM(p<0.0001). The Gleason score is defined as follows, if the score is 
6 or less it is considered to be low grade or well differentiated. The Gleason score 7 is 
defined as moderately differentiated or intermediate grade. Gleason score of 8 to 10 is 
considered to be poorly differentiated or high grade. This table indicated that AAM on a 
whole have a higher grade and percentage than their counterparts. 
Table 4 
Frequency of Men With Advanced Stage of Disease Based on Gleason Score 
Race Gleason 5 < Gleason 6 Gleason 7 Gleason 8-10 
AAM 664 (1%) 20285 (44%) 19293 (42%) 5623 (12%) 
EAM 3182 (1%) 112304 (47%) 93405 (39%) 29750 (12%) 
Total 3846 132589 112698 35373 
Note. Chi-square = 154.3135. p value = < 0.0001. 
 
Table 5 will discuss the risk of disease related to race and the levels of risk. This 
covers the male population between AAM and EAM. In looking at the risk here I do not 
see any difference between AAM and EAM in the United States. The percentages are 




Percentages of AAM and EAM for Different Levels Based on the Risk of Acquiring 
Prostate Cancer in the United States 
 
Race Low Intermediate High 
AAM 13717 (30%) 21306 (46%) 10842 (24%) 
EAM 75534 (32%) 110564 (46%) 52543 (22%) 
Total 89251 131870 63385 
Note. Chi-square = 82.8356. p value = < 0.0001. 
The data presented designates the baseline for this study. In the previous section I 
did not separate rural from urban. Rural and urban are now presented to justify and 
answer my research questions. Table 6 represents an analysis performed based on age and 
demographics. I looked at rural AAM and EAM together by age less than 50 years with 
20,000 or less in population. N = 431 (2%) compared to urban population within the 
same age group, N = 8813 (3%) with the population being 20,000 or greater. The age 
between 50-59 years for rural population N= 3795 (19%) compared to urban where 
N=59446 (23%). The next age group continued with 60–69 years with rural N = 8366 
(42%), compared to urban at same age N = 105365 (41%). At age 70–79 years rural 
population N = 6036 (30%) compared to urban population N = 67534 (26%). The final 
age observed both groups of men at 80 or greater in years. The rural analysis was N = 
1443 (7%) compared to urban N = 16026 (6%). Looking at this data there did seem to be 
and difference statistically with percentage, and age. I did take into consideration that the 
rural population will be less than the urban population, however in comparison the 




Frequency of Rural Versus Urban Population Based on Age 
Rural/Urban < 50 yr. 50–59 yr. 60–69 yr. 70–79 yr. > 80 yr. 
Urban > 20k  8813 (3%) 59446 (23%) 105365 (41%) 67534 
(26%) 
16026 (6%) 
Rural < 20k  431 (2%) 3795 (19%) 8366 (42%) 6036 (30%) 1443 (7%) 
Total 9244 63241 113731 73570 17469 
Note. Chi-square = 367.3265. p value = < 0.0001. 
 I continued to compare rural versus urban based on marriage, PSA, Gleason 
score, and risk. The data showed significant different if the men were married versus not 
being married. The total number of men married in rural community was N = 14665 
(73%) versus the urban community N = 180631 (70%). This was compared to not 
married category rural N = 5406 (27%), and urban N = 76563 (30%). Table 7 will display 
the finding presented for this variable.  
Table 7 
Results of Married Versus Not Married Men With Prostate Cancer in Rural Versus 
Urban Communities 
 
Race Not married Married Total 
AAM 19781 (43%) 26084 (57%) 45865 (100%) 
EAM 64670 (27%) 173971 (73%) 238941 (100%) 
Total 84451 200055 284506 




Following in sequence I proceeded to analyze PSA in rural and urban 
communities for comparison. The data suggested that there was statistically no difference 
within the communities. Which is consistent with earlier findings when I did PSA in the 
United States and did not compare to the different communities? Table 8 demonstrates 
the findings and the percentages along with the P value and Chi–square results. 
Table 8 
PSA Analysis From Men Diagnosed With Prostate Cancer in the United States 
Race PSA < 1 PSA > 1 PSA > 2 PSA > 4 PSA > 10 PSA > 20 
AAM 681 (1%) 991 (2%) 4515 
(10%) 














Total 5453 7934 33912 181769 41549 13889 
Note. Chi-square = 1.2e +03. p value = < 0.0001. 
Table 9 will display the advanced stage of disease between urban and rural 
communities based on the definition of urban and rural. This data suggest that there is a 
slight difference in advance stage disease between urban and rural with rural having the 
highest percentage. The lower Gleason scores show that there is no difference whether it 
is rural or urban, this can be explained based on the number of individuals reported at the 
time. The population of the urban community is larger than that of rural. The difference 




Gleason Score of Rural Versus Urban Communities for Men Diagnosed With Prostate 
Cancer 
 
Rural/Urban Gleason 5 < Gleason 6 Gleason 7 Gleason 8-10 
Urban >20K  3304 (1%) 120320 (47%) 101881 (40%) 31689 (12%) 
Rural < 20K  447 (2%) 8782 (44%) 8087 (40%) 2755 (14%) 
Total 3751 129102 109968 34444 
Note. Chi-square = 190.6405. p value = < 0.0001. 
Risk of disease between rural and urban data suggest that rural communities’ 
population risk is greater than urban population. The results from the data suggest, the 
higher the risk the greater chance that the rural population of men will be diagnosed with 
prostate cancer. Table 10 will display data and confirm the findings, which were stated 
throughout this dissertation.  Risk of disease was based on low, intermediate, and high 
ratios. 
Table 10 
Risk of Disease Between Rural Versus Urban Communities With Population Being 20k 
and Greater for Urban and 20k and Less for Rural 
 
Rural/Urban Low Intermediate High 
Urban > 20K  81441 (32%) 119059 (46%) 56694 (22%) 
Rural < 20K  5520 (28%) 9477 (47%) 5074 (25%) 
Total 86961 128536 61769 
Note. Chi-square = 193.8793. p value = < 0.0001. 
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Testing the Research Questions and Hypotheses 
The research questions guided this study on the complexity of prostate cancer 
diagnosis in AAM. Pending the statistical analysis the null hypotheses was presumed to 
be proven true. The research questions used to guide this study are being addressed in this 
chapter. Descriptive data associated with the variables coming from the SCT model, race, 
age, demographics, and marital status were incorporated in this study to determine 
prostate cancer behaviors between AAM and EAM in rural and urban communities. 
Another set of variables, PSA, Gleason Score, and demographics were incorporated to 
address the severity of prostate cancer in AAM versus EAM leaving in rural versus urban 
communities. The results of the data analyzed are shown below with an explanation of 
the data researched. The statistics performed here are from SPSS using chi-square results 
along with p-value and percentage. 
RQ1: Is there a significant difference between the proportion of AAM and EAM 
annually diagnosed with prostate cancer in rural areas in the United States during 
a five-year period? 
Ho1: There is no significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in rural areas in the United 
States over a 5-year period. 
Ha1: There is a significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in rural areas in the United 
States over a 5-year period. 
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Results of the chi-square test of independence for race and demographics returned 
significant results with P Value = <0.05 with differences in risk and age of AAM and 
EAM annually diagnosed with prostate cancer. Table 11 demonstrates the data collected 
with the comparison by age and race utilizing SPSS statistics for standard deviation and 
mean. Table 12 shows the relationship of significance by chi-square results as it relates to 
risk in both AAM and EAM leaving in rural versus urban communities. Table 13 list the 
relationship of significance by chi-square and logistic regression results, over a period of 
five years in an urban development, based on race, age and marital status. Based upon the 
data collected and presented in the tables for Research Question 1, the null hypothesis 
was rejected in lieu of the alternative hypothesis which suggests there is a significant 
difference between the populations.  
Table 11 
Age-Related Comparison of Men Diagnosed With Prostate Cancer Based on Race in 
Rural Versus Urban Communities 
 
Race Obs. Mean Std. dev. Min Max 
AAM 45864 63.11876 8.966572   32   98 
EAM 238632 65.98336 8.921155   23   106 
 
This table demonstrates that AAM are diagnosed with advance stage disease at a 
younger age that EAM demonstrating that by the mean age between the groups. This 




Risk of AAM Compared to EAM Living in Rural Communities Diagnosed With Advanced-
Stage Prostate Cancer in the United States  
 
Race Low Intermediate High 
AAM 13156 (30%) 20350 (47%) 10220 (23%) 
EAM 70575 (32%) 102043 (46%) 48091 (22%) 
Total 83731 122393 58311 




Logistic Regression Results of AAM and EAM in a Rural Community Over a 5-Year 
Period in the United States 
 
Risk Odds ratio Std. err Z P > |Z| 95% con Interval 
Race 1.195584 .0149599 14.2 0.000 1.16662 1.225267 
Age < 50 .7841884 .0226188 -8.43 0.000 .7410862 .8297975 
Age 50-59 .8588257 .0109672  0.000 .8375971 .8805924 
Age 60-69 1.35079 .0152409 26.65 0.000 1.321246 1.380994 
Age > 80  2.850909 .0488717 61.11 0.000 2.756714 2.948324 
Yr. diag. 
2005 
1.014481 .0189019 0.77 0.440 .9781027 1.052213 
Yr. diag. 
2006 
.9933613 .0180541 0.37 0.714 .9585988 1.029384 
Yr. diag. 
2007 
.872721 .0158623 -7.49 0.000 .8421786 .904371 
Yr. diag. 
2008 
.8920351 .0164345 -6.20 0.000 .8603987 .9248348 
Yr. diag. 
2009 
.8613282 .0159871 -8.04 0.000 .8305572 .8932392 
Yr. diag. 
2010 
.8819796 .0164733 -6.72 0.000 .8502763 .914865 
Yr. diag. 
2011 
.8483067 .015989 -8.73 0.000 .8175406 .8802305 
Married .9383218 .0095058 -6.28 0.000 .9198745 .9571391 
Rural 1.177914 .0202005 9.55 0.000 1.138979 1.218179 




RQ2: Is there a significant difference in the proportion of AAM and EAM living 
in urban areas in the United States annually diagnosed with prostate cancer during 
a five-year period? 
Ho2: There is no significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in urban areas in the United 
States in a 5-year period. 
Ha2: There is a significant difference between the proportion of AAM and 
EAM annually diagnosed with prostate cancer in urban areas in the United 
States in a 5-year period. 
The finding of the chi-square test for independence comparing AAM and EAM 
annually diagnosed with prostate cancer in the United States over a five-year period 
living in urban areas showed statistically results (P Value =<0.05) with differences 
between race and demographics. Table 14 list the relationship of significance by chi-
square and logistic regression results, over a period of five years in an urban 
development, based on race, age and marital status. Based upon the data collected and 
presented in the tables for Research Question 2, the null hypothesis was rejected in lieu of 





Logistic Regression Results of AAM and EAM in an Urban Community over a 5-Year 
Period in the United States 
 
Risk Odds/Ratio  Std. err Z P > |Z| 95% con Interval 
Race 1.189103 .0153118 13.45 0.000 1.159468 1.219496 
Age < 50 .7844002 .0226254 -8.42 0.000 .7412855 .8300226 
Age 50-59 .858854 .0109677 -11.92 0.000 .8376245 .8806215 
Age 60-69 1.350809 .0152413 26.65 0.000 1.321265 1.381014 
Age > 80  2.850468 .0488651 61.10 0.000 2.756285 2.947869 
Yr. diag. 
2005 
1.014548 .0189033 0.78 0.438 .9781662 1.052282 
Yr. diag. 
2006 
.9933032 .0180532 -0.37 0.712 .9585424 1.029325 
Yr. Diag. 
2007 
.8727535 .0158631 -7.49 0.000 .8422097 .904405 
Yr. diag. 
2008 
.8920568 .016435 -6.20 0.000 .8604194 .9248575 
Yr. diag. 
2009 
.8613973 .0159885 -8.04 0.000 .8306236 .8933112 
Yr. diag. 
2010 
.8820471 .0164747 -6.72 0.000 .8503411 .9149352 
Yr. diag. 
2011 
.8483218 .0159893 -8.73 0.000 .8175551 .8802464 
Married .9384848 .0095081 -6.27 0.000 .9200331 .9573065 
Urban 1.16468 .0212917 8.34 0.000 1.123688 1.207168 
Note. Number of ods. = 277255. LR chi-square = 5524.05. Prob. > Chi2         0. 
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RQ3: Was there a significant change in the proportion of men annually diagnosed 
with advanced stage prostate cancer in rural versus urban areas in the United 
States during a five-year period? 
Ho3: The proportion of men annually diagnosed with advanced stage 
disease in a rural community versus an urban community did not change 
during the 5-year period. 
Ha3: The proportion of men annually diagnosed with advanced stage 
disease in a rural community versus an urban community changed 
significantly during the 5-year period.  
The chi-square test results of independence comparing AAM and EAM annually 
diagnosed with advanced stage disease in rural versus urban community showed 
statistically significant results (P Value =<0.05) with stage of disease based on Gleason 
Score. Additional findings showed significant difference in the logistics regression results 
the 95% CI was (1.1 – 1.3). These results are explained in Table 15 and 16. Based upon 
the data collected and presented in the tables for Research Question 3, the null hypothesis 
was rejected in lieu of the alternative hypothesis which suggests there is a significant 




Advanced-Stage Disease of Men Diagnosed With Prostate Cancer Over 5-Year Period 
Based on Race, Age, and Gleason Score 
 
Race Gleason 5 < Gleason 6 Gleason 7 Gleason 8-10 
AAM 600 (1%) 19434 (44%) 18371 (42%) 5321 (12%) 
EAM 2799 (1%) 104373 (47%) 86240 (39%) 27297 (12%) 
Total 3399 123807 104611 32618 





Logistic Regression Results of AAM and EAM Over a 5-Year Period in the United States 
Risk Odds/Ratio  Std. err Z P > |Z| 95% con Interval 
Race 1.216631 0.053902 4.43 0 1.115442 1.326999 
Age < 50 0.8837661 0.0902663 -1.21 0.226 0.7234309 1.079637 
Age 50-59 0.850692 0.0352071 -3.91 0 0.784412 0.9225725 
Age 60-69 1.365693 0.0465331 9.15 0 1.277469 1.460011 
Age > 80  3.268155 0.1687957 22.93 0 2.953515 30616313 
Yr. diag. 
2005 
0.9947706 0.0571956 -0.09 0.927 0.8887549 1.113432 
Yr. diag. 
2006 
0.9575623 0.0533845 -0.78 0.437 0.8584445 1.068124 
Yr. diag. 
2007 
0.7785422 0.0437576 -4.45 0 0.6973338 0.8692077 
Yr. diag. 
2008 
0.8316075 0.0474698 -3.23 0.001 0.7435842 0.9300507 
Yr. Diag. 
2009 
0.7960569 0.0462707 -3.92 0 0.710343 0.8921134 
Yr. diag. 
2010 
0.823038 0.0477311 -3.36 0.001 0.7346078 0.9221133 
Yr. diag. 
2011 
0.8962405 0.0516204 -1.9 0.057 0.8005681 1.003346 
Married 0.9375667 0.0296691 -2.04 0.042 0.881183 0.9975583 
Note. Number of ods. = 27312. LR chi-square = 724.71. Prob > Chi2         0. 
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RQ4: Did PSA levels of men annually diagnosed with advanced stage prostate 
cancer significantly changes in rural versus urban areas in the United States 
during a five year period? 
Ho4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community did not 
change during the 5-year period. 
Ha4: The PSA levels of men annually diagnosed with advanced stage 
prostate cancer in a rural community versus an urban community changed 
significantly during the 5-year period. 
The finding of the chi-square test for independence comparing AAM and CM 
annually diagnosed with prostate cancer in the United States over a five-year period 
living in urban versus rural areas, PSA levels showed statistically results (P Value = < 
0.05) with differences between race and demographics and Gleason Score. Table 17 list 
the relationship of significance by chi-square test results, over a period of five years in an 
urban development, and a rural development based on race, PSA, and demographics. 
Based upon the data collected and presented for Research Question 4, the null hypothesis 
was rejected in lieu of the alternative hypothesis which suggests there is a significant 




PSA Analysis for Men Diagnosed With Prostate Cancer, Rural Versus Urban 
Communities 
 
Race  PSA < 1 PSA > 1 PSA > 2 PSA > 4 PSA > 10 PSA > 20 
AAM 652 (1%) 953 (2%) 4369 (10%) 27084 (62%) 7697 (18%) 2971 
(7%) 
EAM 4455 (2%) 6529 (3%) 27757 (13%) 142017 (64%) 30333 (14%) 9585 
(4%) 
Total 5140 7482 32126 169101 38030 12556 
Note. Chi-square = 1.2e+03. p value = < 0.0001. 
Summary 
Research questions and hypotheses statements were analyzed in chapter four. The 
variables used in this study were used to perform descriptive statistical analyses. The 
dependent variables consisted of race, demographics, advance stage of disease and PSA 
levels. Information regarding the study research questions and hypothesis pertaining to 
the statistical analysis was presented in this chapter and all assumptions regarding the 
study were met.  
Statistical analysis was performed using chi-square test and logistic regression as 
related to the variables of study. The chi-square tests were a priori and demonstrated a 
statistical significance for the entire variables mentioned above. The logistic regression 
analysis was investigative by nature; nevertheless, the results showed a statistical 
significance for all variables either dependent or independent. The logistic regression 
models the relationship between a dependent variable and one or more independent 
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variables. In this study race was a dependent variable and marital status and age were 
independent. Each test for the various research questions indicated a significant 
difference was presented and the null hypotheses were each rejected in lieu of the 
alternative hypotheses. 
Chapter 5 will provide a more detailed explanation and interpretation of the 
results also will give recommendations for future studies and a plan for action. Chapter 5 
will discuss social change to improve the health of AAM in the United States and may 
provide interest in continuing one to want better understanding as to why prostate cancer 
has a higher incidence in AAM. 
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Chapter 5: Discussion 
Introduction 
This chapter presents a discussion of the findings discovered in Chapter 4 and the 
study’s implications for social change, as well as limitations of the study and 
recommendations for action and studies to be conducted in the future. Prostate cancer 
endures as the most commonly diagnosed cancer in men in the United States. AAM are 
more at risk of receiving a prostate cancer diagnosis at an advanced stage than U.S. men 
of other ethnic groups. Understanding prostate cancer signs and symptoms and having 
awareness of risk factors related to prostate cancer may allow AAM the opportunity to 
decide whether screening or any other modality is beneficial for them. 
The purpose of this study was to assess demographic variables, race, PSA, and 
advanced stage of disease in AAM versus EAM and rural versus urban communities in 
the United States over a period of time. The reason for the study was the high incidence 
of prostate cancer in AAM. The majority of past research in this area has focused on 
treatment. This study concentrated on diagnosis of prostate cancer in AAM in rural areas 
versus urban areas. This study used chi-square test and logistic regression to analyze the 
data.  
This study, even though it was focused on diagnoses, opens the door for future 
research on prostate cancer in AAM and its relationship with metastatic disease. 
Evaluating and statistically analyzing the data led to questions relating to primary tumor 
and metastatic disease. I looked at the relationship of metastatic disease and AAM in 
rural versus urban communities, because some data pointed to EAM in rural areas as 
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having a higher percentage of advanced-stage disease than AAM in urban areas. Future 
research on prostate cancer diagnosis is necessary to clean up these phenomena generated 
by this study in the public health arena. 
Interpretation of Findings 
 Examining my research questions, I listed each one separately and explained the 
findings as related to Chapter 4. Research Question 1 was the following: Is there a 
significant difference between the proportion of AAM and the proportion of EAM 
annually diagnosed with prostate cancer in rural areas in the United States during a 5-year 
period? The results showed that there is a statistically significant difference (p <0.005) 
between AAM and EAM in rural areas within the United States. The chi-square test was 
used to generate the results to address this question. An additional step was taken to 
consider marriage and to determine whether there was a significant difference here. The 
results did show a significant difference (P < 0.005), however, this was not part of the 
research question; I assumed that the data would play an important role in future studies. 
 AAM in rural areas are particularly at risk of late-stage cancer diagnosis. It is also 
documented that rural dwellers have less access to and are less likely to use early cancer 
detection programs (Goovaerts & Xiao, 2011). This statement is supported by the data 
that were collected for this study. Even though numerous studies have highlighted the 
need for prostate cancer screening among AAM, no studies have addressed the concerns 
and attitudes of rural AAM about prostate cancer diagnosis and cancer screening 
programs (Oliver, 2007).  
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Research Question 2 was the following: Is there a significant difference in the 
proportion of AAM and the proportion of EAM living in urban areas in the United States 
annually diagnosed with prostate cancer during a 5-year period? The results showed that 
there is a statistically significant difference (p val < 0.005) between AAM and EAM in 
urban areas within the United States. The chi-square test was used to generate the results 
to address this question. Table 14 lists the relationship of significance by chi-square and 
logistic regression results over a period of 5years in an urban development, based on race, 
age, and marital status.  Age group showed statistical significance (p val < 0.005) using 
the logistic regression table and chi-square results.  
It has been reported that changes in the prevalence of risk factors in the AAM 
population will impact what has been reported and the real incidence of the disease 
(Heyns, 2008). Depending on exposure and the effects on the stage of the prostate 
cancer’s natural history, some of these changes in exposure will cause changes in 
incidence, whereas others may take some time to become evident in AAM (Brawley, 
2012b). It should be mentioned that for grades of prostate cancer, AAM have a higher 
rate than EAM in the United States, and the disparity is very pronounced for 
undifferentiated prostate tumors. 
Research Question 3: was there a significant change in the proportion of men 
annually diagnosed with advanced-stage prostate cancer in rural versus urban areas in the 
United States during a 5-year period? The chi-square test results of independence 
comparing AAM and EAM annually diagnosed with advanced-stage disease in rural 
versus urban communities showed statistically significant results (p val < 0.05) with stage 
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of disease based on Gleason score. Additional findings showed significant difference in 
the logistic regression results; the 95% CI was (1.1 – 1.3). 
The difference in the extent of prostate cancer diagnosis between AAM and EAM 
may suggest a rural versus urban disparity for populations within these regions. The study 
acknowledged that in comparison to EAM, AAM have been diagnosed with a higher 
grade and more advanced stage of prostate cancer in both rural and urban communities. 
The data was verified in Tables 13, 14, and 15 which represent the logistic regression and 
chi-square results for significant difference. 
Clinically advanced stage prostate cancer was detected more repeatedly in AAM 
than in any other ethnic group (Brawley, 2012b). Clinical, socioeconomic, and pathologic 
factors have been known to account for 15% of the increased risk in AAM (Oliver, 
2007). Being diagnosed with advanced-stage prostate cancer is a major health problem 
for AAM living in a low-income environment. This causes opportunities to vary for early 
detection, leading to an explanation for why AAM were twice as likely to be presented 
with advanced-stage prostate cancer.  
Research Question 4 was as follows: Did PSA levels of men annually diagnosed 
with advanced-stage prostate cancer significantly change in rural versus urban areas in 
the United States during a 5-year period? In the findings of the chi-square test for 
independence comparing AAM and EAM annually diagnosed with prostate cancer in the 
United States over a 5-year period living in urban versus areas, PSA levels showed 
statistically significant results (p val <0.05) with differences between race and 
demographics and Gleason score. Significant differences within the age group and racial 
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group showed AAM having a lower mean for age, and their PSA levels were reported as 
significantly higher. 
Although marital status was not a variable of concern, I did use some of the 
results to determine whether there was a statistically significant difference in relationship 
to PSA levels in AAM and EAM who were married and not married. Results showed at 
statistically significance (p val<0.005) by virtue of the chi-square test. This was 
demonstrated in Tables 7 and 8.  
Chi-square test and logistic regression were performed to test the four research 
questions and hypotheses and examine the variables over the 5-year period in this study. 
The test measured percentage, frequency, p value, and 95% CI of disease among different 
demographic areas and populations based on race and age. The chi-square test was 
considered a priority in the study. Data showed that all the variables of study had 
statistical significance. Overall, the results of the study showed that there was a statistical 
difference in rural versus urban populations between AAM and EAM diagnosed with 
prostate cancer over a 5-year period. 
PSA is at present the most reliable marker for prostate cancer with a higher 
predictive value. This antigen was introduced into practice in 1986 for use in prostate 
cancer screening (Heyns, 2008). PSA is more useful in deciding if an individual needs a 
biopsy that in determining stage of disease. Some studies have shown higher PSA values 
in AAM than EAM, however, some of these same studies have pointed to other factors 
such as large tumors, undetected metastasis, and more aggressive tumor biology in AAM 
as the reason for advanced-stage disease (Brawley, 2012b). 
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A finding that was not expected from the data was EAM in rural populations had 
a statistical significance when compared to AAM in urban populations. I was not looking 
for this in this study, however when I compared the results this stood out. More research 
is needed in order to confirm this hypothesis. Preliminary data points to EAM in rural 
areas have higher frequency of being diagnosed with prostate cancer when compared to 
AAM in urban areas. 
Limitations of Study 
One limitation of the study is that the sample size coming from the SEER 
database was not equal for urban demographics and rural demographics. This is 
understood because the population in an urban setting is larger than that of rural. 
Preferably a yearly census data may give greater insight into the true population of rural 
areas. 
The strength of the study was that the data was collected the same way without 
any adjustments having to be done by the researcher. However, with this being said recall 
bias maybe a limiting factor because of the patients not having entire information and 
understanding of their disease. SEER has standards as to how data is collected and used; 
this made this study more reliable for the findings that are presented. A larger number of 
men in rural communities would have provided a greater insight and outcome on the 
differences in the study compared to urban men, assuming that PSA levels and advance 
stage of disease may give information on the increase in frequency of prostate cancer in 




Implications for Social Change 
 Could there be a difference in socioeconomic status, lack of education, and lack 
of insurance and less access to quality healthcare? Many might think so, however, this 
study looked at the complexity of why AAM were diagnosed with advance stage disease 
more than CM. Those question asked above would be considered if this study was based 
on treatment. AAM diagnosed with high Gleason Scores show that the stage of the 
disease is severe. Giving them the tools to curtail the high incidence for the disease is 
extremely necessary. This study utilized the Social Cognitive Theory (SCT) to focus on 
AAM, and their behavior with prostate cancer diagnosis, in rural versus urban 
communities. SCT assume that individuals will make a reasonable decision whether one 
should take preventive action (Myers, 2005). A part of the SCT represents a form of 
various life domains, such as family, health, demographic location, employment, and 
health care providers. 
 The implications for social change are to reduce prostate cancer health disparities 
among AAM in the United States. This can be done through knowledge, education, and 
healthcare providers. These results will improve health outcomes and reduce the burden 
of cancer in AAM and their families. Continuous research and designing future studies to 
determine the other cofounders that play a role in the increased incidence rate may 
determine future health outcomes and establish programs that would improve the health 
of AAM as it relates to prostate cancer. This in itself may lead to cultural behavior 
changes within the AAM population. 
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 This study will introduce social change in AAM by entertaining focus groups to 
spread the word to rural and urban communities on the importance to bring prostate 
cancer discussions as the focal point relating to men receiving information their diagnosis 
of prostate cancer in both populations as a suggestion. Examples of these focus groups 
and interventions are reported further in this discussion. AAM have been told of the need 
for early screening for treatment purposes; however this study will increase the 
knowledge in AAM for diagnosis as well as their living environment. Pointing out to 
AAM that diagnosis is a primary concern with prostate cancer disease suggests that AAM 
focus on the need to change behavior when they are diagnosed. 
 Several SCT interventions have been tested in the past and are proven to be 
successful. The interventions that will be beneficial for this study are psychosocial 
interventions, faith based interventions, and group based interventions. Psychosocial 
interventions will provide self-efficacy for AAM to reduce the stress from not meeting 
the educational knowledge of understanding the nature of the disease and will help to 
improve on their quality of life. This type of intervention will provide supportive and 
expressive group therapy for AAM will have effective measures in relaxation training, 
emotional support and assist in an avenue for AAM to express their fears and anxieties, 
along with behavioral and cognitive coping strategies. 
 Given that behavioral choices remain debatably the influential determinant for 
population’s health outcomes, AAM individual behaviors remain a key weapon in 
eliminating prostate cancer health disparities. This study aids in changing the behavior of 
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AAM by pointing out the necessary guidelines needed to become knowledgeable and ask 
the right questions when AAM are diagnosed with advanced stage prostate cancer. 
 Behavioral interventions will influence observance to prostate cancer early 
detection within the AAM population. Individual background and cognitive along with 
psychosocial characteristics may affect AAM behavior. Future research should look into 
the impact that cognitive and psychological correlates with decision making and behavior 
along the gamut of prostate cancer care in AAM. Socioeconomic status and education 
should be reviewed for the role they play in quality of healthcare. 
 Group based intervention programs are structured to manage interventions on 
improving quality of life trough cognitive behavioral management skills. AAM along 
with EAM in rural communities will benefit from this program based on the time it takes 
to travel to health care providers explaining why the high rate of advance disease is seen 
among this population of men, and the data in this study showed that the rural 
communities’ percentage of advanced stage disease was higher. Changing the behavioral 
concept for AAM is very important for the success rate of the disease and decreasing the 
stage of disease along with mortality rate. 
 Social support will enhance health related quality of life in AAM diagnosed with 
prostate cancer by improving their cognitively ability to manage their prostate cancer 
proficiency. Many faith based organizations have lay leaders who educate AAM that 
were diagnosed with prostate cancer who tend to serve as role models for AAM, because 
they themselves have been dealing with the same disease. These interventions are in 
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place for several communities and can be implemented in this study based on data that 
was presented in this study.  
Recommendations 
The results of this study can be of value to AAM, healthcare professionals, family 
members, and friends of AAM. This study focused on prostate cancer diagnosis among 
AAM and EAM living in rural and urban communities. The outcome from the study 
cause for the researcher to recommend that AAM seek early detection programs and 
entertain the idea of joining group based intervention programs to gain knowledge on the 
disease. Which will provide additional education and enhance the knowledge regarding 
prostate cancer to all men involved in the study? Another recommendation is for all men 
to join a focus group in order to discuss each ones diagnosis which will enhance their 
learning about the disease. Another recommendation is to seek information from 
psychosocial intervention programs which will enhance their quality of life and improve 
their self-efficacy.  Having a SCT model to affect a physical transition in AAM will be 
very helpful for improving quality of life in these patients. AAM should be able to make 
an informed decision with their health care providers, only after being informed with 
information about the uncertainties, risk and potential benefits. Having this ammunition 
will give AAM the tools necessary to share with family and friends, so that early 
detection will lead to less frequency of advanced stage prostate cancer in the population. 
This practice will ensure that AAM will be given an opportunity to learn about the 
disease and become aware of the severity that is associated with prostate cancer 
diagnosis. With this knowledge comes health benefits and understanding which will 
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provide quality of life and may increase AAM life expectancy as related to prostate 
cancer.  
Family discussions should take place on a regular basis in order for AAM to 
understand the history which has been present in their background. Attending 
multidisciplinary panels is another recommendation which can set guidelines for AAM to 
follow during their battle with prostate cancer. AAM need to learn more about evidence 
review, consisting of randomized trials, population data, and modeled data which will 
lead to evidence interpretation consisting of public health perspectives and individual 
perspectives to go along with policy. This is the knowledge which is lacking that this 
study will incorporate in the mindset of AAM who seek to conquer the prostate cancer 
dilemma. 
Conclusion 
 Prostate cancer remains an important health concern for all men, however with a 
major emphasis on AAM. This topic will always be controversial in the public health 
realm of study. Recognizing and understanding the risks factors associated with the 
development of prostate cancer, along with the outcome of delayed initial screenings, and 
the diagnosis highlight the importance of this study. The African-American ethnic 
background presents a greater risk of disease with advanced stages, which implies a 
poorer prognosis for AAM. This could reflect the later stages of the diagnosis and 
consequently poorer prognostic features of the disease in AAM, or it could reflect a 
biological difference in the disease. 
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 This study demonstrated the relationship between AAM and EAM living in rural 
and urban communities diagnosed with prostate cancer. The purpose was to examine if 
there was a statistical significance between AAM, EAM, demographics and stage of 
disease. This study showed that there was a statistical significance base on chi-square 
results and p-value. This study was not able to determine the specific reason as to why 
these differences occur, however the changes were significant enough to know that there 
was a difference based on the comparison of the variables used in the study. 
Discovering prevalence among rural and urban populations of this study was 
important in order to observe the frequency for prostate cancer in AAM and EAM living 
in the communities. The logistic regression model showed measures for prevalence over 
time, this justified the PSA results along with advanced stage of disease in both AAM 
and EAM. Chi-square test aided in justifying the significance in the PSA levels and 
advance stage of disease using Gleason score in AAM and EAM living in rural and urban 
populations. 
 Future studies are needed to address some of the results that I encountered from 
this study. Researchers need to look at the association from metastatic disease in 
correlation with advance stage prostate cancer in AAM compared to EAM and 
demographics. This research should be based on information gathered from a qualitative 
methodology, seeking more information from rural populations. Another area of concern 
is this study showed a significant difference in EAM living in rural areas and AAM living 
in urban areas. This need to be evaluated more in order to see if there is indeed more data 
that support the rural populations have the increase percentage for prostate cancer 
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diagnosis and to determine why this phenomena takes place. I would suggest a qualitative 
case control study be conducted to generate more data from the rural population that will 
support any future study finding on the comparison in AAM and EAM in this population.  
 It is extremely essential for public health to continue monitoring evaluating the 
health outcomes for AAM populations who are at risk of being diagnosed with prostate 
cancer no matter where the demographics are. Informed decisions may empower AAM, 
and allow them to make a conscious decision on their health behavior.  Enhancing ones 
knowledge will provide the tools that are necessary for correcting any misunderstandings, 
or misgivings that AAM may have encountered in earlier medical conversations with 
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